1031 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00009 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 6 M |
| dbacp00018 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00027 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00051 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 2.4% inhibition at 10-5 M |
| dbacp00052 | Enkephalins7 analogue-8 | YA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 7.5% inhibition at 10-4 M |
| dbacp00075 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 1.1% inhibition at 10-5 M |
| dbacp00076 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 1.2% inhibition at 10-4 M |
| dbacp00077 | Enkephalins7 analogue-9 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 17.8% inhibition at 10-3 M |
| dbacp00096 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 7.7% inhibition at 10-4 M |
| dbacp00097 | Enkephalins7 analogue-10 | YSA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 18.7% inhibition at 10-3 M |
| dbacp00106 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00115 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00124 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00149 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 21.2% inhibition at 10-3 M |
| dbacp00158 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00182 | Enkephalins7 analogue-16 | YRA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 15.6% inhibition at 10-3 M |
| dbacp00191 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00216 | Enkephalins7 analogue-17 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 22.8% inhibition at 10-3 M |
| dbacp00225 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00250 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 9.6% inhibition at 10-4 M |
| dbacp00251 | Enkephalins7 analogue-18 | YA*GFM | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 29.9% inhibition at 10-3 M |
| dbacp00260 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00269 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00278 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00288 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 2.2% inhibition at 10-6 M |
| dbacp00289 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 7.1% inhibition at 10-5 M |
| dbacp00290 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 6.9% inhibition at 10-4 M |
| dbacp00291 | Enkephalins7 analogue-23 | YGGFMA* | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 25.9% inhibition at 10-3 M |
| dbacp00300 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00325 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 46.2 ± 7.6 μM |
| dbacp00330 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 2.3 ± 0.2 μM |
| dbacp00335 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 30.8 ± 2.0 μM |
| dbacp00340 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 36.2 ± 2.8 μM |
| dbacp00345 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 29.0 ± 3.7 μM |
| dbacp00350 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 6.4 ± 0.6 μM |
| dbacp00355 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 33.3 ±7.4 μM |
| dbacp00360 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 9.5 ± 0.5 μM |
| dbacp00365 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 51.0 ± 4.6 μM |
| dbacp00370 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 4.6 ± 0.2 μM |
| dbacp00375 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 15.6 ± 3.6 μM |
| dbacp00380 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : > 64 μM |
| dbacp00385 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 37.5 ± 3.3 μM |
| dbacp00390 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 1.4 ± 0.2 μM |
| dbacp00395 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 38.5 ± 4.8 μM |
| dbacp00400 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 15.5 ± 0.8 μM |
| dbacp00406 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 22.5 ± 3.3 μM |
| dbacp00411 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 3.0 ± 0.1 μM |
| dbacp00416 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 14.9 ± 0.8 μM |
| dbacp00421 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 51.5 ± 3.9 μM |
| dbacp00426 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 3.9 ± 0.2 μM |
| dbacp00431 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 14.1 ± 0.9 μM |
| dbacp00443 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 19.5 ± 0.5 μM |
| dbacp00448 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 1.7 ± 0.1 μM |
| dbacp00453 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 9.0 ± 0.5 μM |
| dbacp00458 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 44.2 ± 2.2 μM |
| dbacp00463 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 6.7 ± 0.7 μM |
| dbacp00468 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 2.1 ± 0.2 μM |
| dbacp00473 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 9.0 ± 1.1μM |
| dbacp00478 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00483 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 26.5 ± 2.4 μM |
| dbacp00488 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00493 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 14.7 ± 1.5 μM |
| dbacp00498 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 20.9 ± 1.4 μM |
| dbacp00503 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 15.2 ± 1.9 μM |
| dbacp00508 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 1.3 ± 0.1 μM |
| dbacp00513 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 15.7 ±1.1μM |
| dbacp00518 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 10.4 ± 1.0 μM |
| dbacp00523 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 29.4 ± 1.1 μM |
| dbacp00528 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 5.0 ± 0.3 μM |
| dbacp00533 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 34.5 ± 3.6 μM |
| dbacp00538 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 39.4 ± 2.6 μM |
| dbacp00543 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 3.1 ± 0.1 μM |
| dbacp00548 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 18.3 ± 1.4 μM |
| dbacp00553 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00558 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 25.0 ± 2.9 μM |
| dbacp00563 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 17.1 ± 0.7 μM |
| dbacp00568 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 1.0 ± 0.1 μM |
| dbacp00570 | [L9]-P18 | KWKLFKKILKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 3 µM |
| dbacp00576 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : > 64 μM |
| dbacp00581 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 10.3 ± 1.1 μM |
| dbacp00586 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 51.2 ± 4.0 μM |
| dbacp00591 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : > 64 μM |
| dbacp00596 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 48.4 ± 0.7 μM |
| dbacp00601 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 11.5 ± 0.6 μM |
| dbacp00606 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 34.1 ± 3.9 μM |
| dbacp00611 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 30.8 ± 2.5 μM |
| dbacp00618 | [S9]-P18 | KWKLFKKISKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 4 µM |
| dbacp00624 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 30.3 ± 1.1 μM |
| dbacp00629 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00634 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 68.4 ± 9.6 μM |
| dbacp00639 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 50.4 ± 2.4 μM |
| dbacp00644 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 2.7 ± 0.1 μM |
| dbacp00649 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 31.6 ± 1.3 μM |
| dbacp00654 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 5.4 ± 0.3 μM |
| dbacp00659 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 31.3 ± 2.6 μM |
| dbacp00664 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 41.0 ± 4.2 μM |
| dbacp00669 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 15.1 ± 1.4 μM |
| dbacp00674 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 3.9 ± 0.1 μM |
| dbacp00679 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 23.3 ± 0.4 μM |
| dbacp00684 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00689 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 39.7 ± 3.8 μM |
| dbacp00694 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : > 64 μM |
| dbacp00699 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 3.9 ± 0.2 μM |
| dbacp00742 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 39 µM |
| dbacp00743 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 29 µM |
| dbacp00744 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 16 µM |
| dbacp00755 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 18 µM |
| dbacp00756 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 12 µM |
| dbacp00757 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 10 µM |
| dbacp00775 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5 µMo/L |
| dbacp00783 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 6.2 µMo/L |
| dbacp00791 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.7 µMo/L |
| dbacp00799 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.1 µMo/L |
| dbacp00982 | Adenoregulin | GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV | South American frog, Giant leaf frog | Cell membrane disintegration | LDH leakage assay | MDA-MB-231 | Breast cancer | GI50 : 8.06 ± 0.50 µM |
| dbacp01142 | Amphipathic peptide CT1 | MKTQFVILIVAVVLLQLISHSEAFLGALWNVAKSVFGKRGLRNFDDLDDTFEPEMSEADLKYLQDLLR | Scorpions, Morelos, located in South-Central Mexico (Mexican scorpion) | Not specified | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 6.3-12.5 μM |
| dbacp01156 | Ant-p53pep | GSRAHSSHLKSKKGQSTSRHKKWKMRRNQFWVKVQRG | Not found | Apoptosis inducing | Annexin V-FITC Binding assay | MDA-MB-468 | Breast cancer | IC50 : 30 µM |
| dbacp01186 | APQQ | NA | Synthetic construct | Cell metatstasis inhibition | Transwell assay | MDA-MB-231 | Breast cancer | Not found |
| dbacp01187 | APQQ | NA | Synthetic construct | Cell metatstasis inhibition | Transwell assay | MCF-7 | Breast cancer | Not found |
| dbacp01251 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10-100 µM |
| dbacp01260 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10-100 µM |
| dbacp01270 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01280 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01300 | Aurein-1.3 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | MDA-MB-468 | Breast cancer | IC50 : 5 μM |
| dbacp01319 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Not specified | Not specified | Not found | Breast cancer | Not found |
| dbacp01328 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Not specified | Not specified | Not found | Breast cancer | Not found |
| dbacp01337 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Cell membrane disintegration | One-dose and five-dose assay | HS 578T | Breast cancer | IC50 : 5 μM |
| dbacp01342 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Breast cancer | LC50 : 10-5 - 10-4 M |
| dbacp01355 | Aurein-2.7 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | MDA-MB-231/ATCC | Breast cancer | IC50 : 5 μM |
| dbacp01366 | Aurein-3.1 [Cleaved into: Aurein-3.1.1; Aurein-3.1.2] | GLFDIVKKIAGHIAGSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | BT-549 | Breast cancer | IC50 : 5 μM |
| dbacp01379 | Aurein-3.2 | GLFDIVKKIAGHIASSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | MDA-N | Breast cancer | IC50 : 5 μM |
| dbacp01391 | Aurein-3.3 [Cleaved into: Aurein-3.3.1] | GLFDIVKKIAGHIVSSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | MCF7 | Breast cancer | IC50 : 5 μM |
| dbacp01405 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01414 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01423 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Breast tumor cell line | Breast cancer | LC50 : 10 µM |
| dbacp01452 | Bassianolide nonribosomal cyclodepsipeptide synthetase | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDYFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDGHGRVFSLQPTTDLTESENGDHLSTPASERTVVIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCALNQSVSKVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTAGDDEIHQVLEESEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVRNAGDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQAVVGRCITVDDDLVQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICVPSDHDRMHNIPGFIRQNQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKIDDSSRDPNNLGWAIGAHSWIINPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQVVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEDTFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFRTQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFTQLKVEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILRVEEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAQVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLERVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGSDELTRPVHPIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDETSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYPAEPGVRTLFQFPTDNDVRMSAPLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | MDA-MB-231 | Breast cancer | Not found |
| dbacp01455 | Bassianolide nonribosomal cyclodepsipeptide synthetase (BSLS) | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDCFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDEHGRVFSLQPTTDLVESENGDCLSTPASERTVGIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCAPNQSVSEVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTASADEIHHVLEEPEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVKNADDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQTVVGRCITVDDDLFQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICIPSDHDRMHNIPGFIRQSQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKISDSSRDPNNLGRAIGSHSWIVNPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQAVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEETFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFATQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFIQLKIEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILHVQEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAHVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLEQVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGPDELTRPVHLIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDDTSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYHPAEPDVRTLFQFPTDNDVRMSALLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | MDA-MB-231 | Breast cancer | Not found |
| dbacp01529 | BC46 | c[(bA)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01534 | BC48 | c[(bA)GRKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01539 | BC49 | c[(bA)(4aba)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01544 | BC50 | c[(4aba)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01549 | BC70 | c[(bA)(k)RKD(1-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01554 | BC71 | c[(bA)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01559 | BC72 | c[(bA)(o)RKD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01564 | BC74 | c[(bA)(k)(Fguan)KD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01569 | BC75 | c[(bA)(k)RKD(D-Bip)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01574 | BC81 | c[(2233tmpa)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01579 | BC83 | c[(bA)(k)RKD(D-2Anth)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01584 | BC84 | c[(bA)(k)RKD(w)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp01606 | BIM | RPEIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01684 | BIM EL - I146Y | LRPEIRYAQELRRIGDEFNE | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01685 | BIM EL -CST-2A | PQMVILQLLAFIFALVWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01686 | BIM EL -I153M | LRPEIRIAQELRRMGDEFNE | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01687 | BIM EL -Q148R | LRPEIRIARELRRIGDEFNE | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01688 | BIM EL -V192E | PQMVILQLLRFIFRLEWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01689 | BIM EL I146Y-I153M | LRPEIRYAQELRRMGDEFNE | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01690 | BIM EL- I181E | PQMVELQLLRFIFRLVWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01691 | BIM EL- I188E | PQMVILQLLRFEFRLVWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01692 | BIM EL-CTS | PQMVILQLLRFIFRLVWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01693 | BIM EL-L185E | PQMVILQLERFIFRLVWRRH | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01713 | BIM FA1 | RPEIWIAQELRRAGDVLNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01715 | BIM FD1 | RPEIWLAQYLRRLGDQINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01717 | BIM FD2 | RPEIWMAQVLRRFGDLLNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01719 | BIM FW1 | RPEIWIAQGLRRIGDTWNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp01912 | BpirLAAO-I | ADDKNPLEEFRETNYEVFLEIAKNGLKATSNPKRVVIVGAGMAGLSAAY | Venom base | Inducing apoptosis | MTT assay | SKBR-3 | Breast cancer | Not found |
| dbacp01995 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 15.1 µg/ml |
| dbacp01996 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | NCI/ADR-RES | Breast cancer | IC50 : 11.5 µg/ml |
| dbacp01997 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | IC50 : 11.3 µg/ml |
| dbacp01998 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HS578T | Breast cancer | IC50 : 11.7 µg/ml |
| dbacp01999 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | MDA-MB-435 | Breast cancer | IC50 : 11.3 µg/ml |
| dbacp02000 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | MDA-N | Breast cancer | IC50 : 10.6 µg/ml |
| dbacp02001 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | BT-549 | Breast cancer | IC50 : 12.9 µg/ml |
| dbacp02002 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | T-47D | Breast cancer | IC50 : 23.9 µg/ml |
| dbacp02112 | cMastoparan-C(cMP-C) | CLNLKALLAVAKKILC | Synthetic construct | Apoptosis | MTT assay | MCF-7 | Human breast cancer | IC50 : 13.66 μM |
| dbacp02113 | C-1 | KWKLFKKIPFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 26 µM |
| dbacp02116 | C-10 | KWKLFKKIPKFLH | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : <100 µM |
| dbacp02119 | C-2 | KWKLFKKIPKFLHLAKK | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 38 µM |
| dbacp02122 | C-3 | KWKLFKKIPLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 79 µM |
| dbacp02125 | C-4 | KWKLFKKIPKFLHLAK | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 54 µM |
| dbacp02128 | C-5 | KWKLFKKIPHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 100 µM |
| dbacp02131 | C-6 | KWKLFKKIPKFLHLA | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 47 µM |
| dbacp02134 | C-7 | KWKLFKKIPLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : <100 µM |
| dbacp02137 | C-8 | KWKLFKKIPKFLHL | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 83 µM |
| dbacp02140 | C-9 | KWKLFKKIPLKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : <100 µM |
| dbacp02234 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 44 µM |
| dbacp02238 | CA-MA-P | KWKLFKKIPKFLHSAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 20 µM |
| dbacp02244 | CA-MA1 | KWKLFKKIKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 100 µM |
| dbacp02248 | CA-MA2 | KWKLFKKIPKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 28 µM |
| dbacp02252 | CA-MA3 | KWKLFKKIGPGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : >100 µM |
| dbacp02272 | Camel | KWKLFKKIGAVLKVL | Ceropin-Melittin hybrid | Cell swelling and rupture of the plasma membrane | MTT/MTS assay | 4T1 | Breast cancer | LC50 : 6.2 µM |
| dbacp02284 | Cancer stem-like cells CD44 peptide-specific CTLs | YIFYTFSTV,LILAVCIAV,SLLALALIL,IILASLLAL,WLIILASLL,VLLQTTTRM,GLVEDLDRT,TVGDSNSNV | Cancer stem-like cells CD44 peptide-specific CTLs | Cell membrane penetrating | Not specified | MCF-7 | Breast cancer | Not found |
| dbacp02306 | Caspase 3 inhibitor | DEVD | Caspase 3 inhibitor | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 65% cytotoxicity at 20 µM approx. |
| dbacp02307 | Caspase 3 inhibitor | DEVD | Caspase 3 inhibitor | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 65% cytotoxicity at 30 µM |
| dbacp02308 | Caspase 3 inhibitor | DEVD | Caspase 3 inhibitor | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 65% cytotoxicity at 40 µM |
| dbacp02358 | Cecropin B | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL | Silkmoth | Pore formation at the cytoplasmic membrane | MTT/MTS assay | BTS-30 | Breast cancer | IC50 : 24.8 µM |
| dbacp02366 | Cecropin B | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL | Silkmoth | Pore formation at the cytoplasmic membrane | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 42.5 µM |
| dbacp02369 | Cecropin B | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL | Silkmoth | Pore formation at the cytoplasmic membrane | MTT/MTS assay | MCF-7R | Breast cancer | IC50 : 24.5 µM |
| dbacp02372 | Cecropin P1 | SWLSKTAKKLENSAKKRISEGIAIAIQGGPR | Small Intestine of Pig | Pore formation at the cytoplasmic membrane | MTT/MTS assay | BTS-30 | Breast cancer | IC50 : >100 µM |
| dbacp02398 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 39.8 ± 1.0 μM |
| dbacp02403 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 2.9 ± 0.1 μM |
| dbacp02408 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 71.7 ± 9.2 μM |
| dbacp02413 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : > 64 μM |
| dbacp02418 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 15.3 ± 1.4 μM |
| dbacp02423 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 2.7 ± 0.1 μM |
| dbacp02428 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 12.7 ± 1.1 μM |
| dbacp02469 | ChBac3.4 | RFRLPFRRPPIRIHPPPFYPPFRRFL | Goat | Cell necrosis; Inhibiting processes of protein synthesis; Damaging the mitochondrial membrane | TUNEL assay, Reactive oxygen intermediates (ROS) assay | Not specified | Breast cancer | Not found |
| dbacp02482 | Chrysophsin-1 | FFGWLIKGAIHAGKAIHGLIHRRRH | Red sea bream, The pyloric caeca and gills | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp02486 | Chrysophsin-1 | FFGWLIKGAIHAGKAIHGLIHRRRH | The pyloric caeca and gills; Red sea bream | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp02496 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp02507 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp02545 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | Not specified | SK-BR-3 | Breast cancer | Not found |
| dbacp02546 | Conotoxin Cl14.1a (Conotoxin Cal14.1a) | MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC | California cone | Apoptosis | Not specified | MCF-7 | Breast cancer | Not found |
| dbacp02547 | Copal-8-ol diphosphate hydratase TPSSA3 | MTSVNLSRAPAAITRRRLQLQPEFHAECSWLKSSSKHAPLTLSCQIRPKQLSQIAELRVTSLDASQASEKDISLVQTPHKVEVNEKIEESIEYVQNLLMTSGDGRISVSPYDTAVIALIKDLKGRDAPQFPSCLEWIAHHQLADGSWGDEFFCIYDRILNTLACVVALKSWNLHSDIIEKGVTYIKENVHKLKGANVEHRTAGFELVVPTFMQMATDLGIQDLPYDHPLIKEIADTKQQRLKEIPKDLVYQMPTNLLYSLEGLGDLEWERLLKLQSGNGSFLTSPSSTAAVLMHTKDEKCLKYIENALKNCDGGAPHTYPVDIFSRLWAIDRLQRLGISRFFQHEIKYFLDHIESVWEETGVFSGRYTKFSDIDDTSMGVRLLKMHGYDVDPNVLKHFKQQDGKFSCYIGQSVESASPMYNLYRAAQLRFPGEEVLEEATKFAFNFLQEMLVKDRLQERWVISDHLFDEIKLGLKMPWYATLPRVEAAYYLDHYAGSGDVWIGKSFYRMPEISNDTYKELAILDFNRCQTQHQLEWIHMQEWYDRCSLSEFGISKRELLRSYFLAAATIFEPERTQERLLWAKTRILSKMITSFVNISGTTLSLDYNFNGLDEIISSANEDQGLAGTLLATFHQLLDGFDIYTLHQLKHVWSQWFMKVQQGEGSGGEDAVLLANTLNICAGLNEDVLSNNEYTALSTLTNKICNRLAQIQDNKILQVVDGSIKDKELEQDMQALVKLVLQENGGAVDRNIRHTFLSVSKTFYYDAYHDDETTDLHIFKVLFRPVV | Clary sage | Apoptotic death | Not specified | SiHa | Metastatic breast cancer | IC50 : 7.10 μM |
| dbacp02574 | Crotamine | YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG | rattlesnake venom,South American rattlesnake | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp02576 | Crotamine | YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG | Venom,South American rattlesnake | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp02597 | Cyclic [W(RW)4 ]-Dox | WRWRWRWRW | Not found | Inhibition of the cell proliferation | MTT/MTS assay | MDA-MB-468 | Breast cancer | 60-79% inhibition of cell proliferation at 1 µM |
| dbacp02599 | Cyclosaplin | RLGDGCTR | Not found | Apoptosis | DNA fragmentation assay | MDA-MB-231 | Breast cancer | IC50 : 2.06 µg/mL |
| dbacp02629 | D-SVS-1 | kvkvkvkvPptkvkvkvk | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 4.7 ± 0.4 µM |
| dbacp02630 | D-SVS-1 | kvkvkvkvPptkvkvkvk | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MDA-MB-436 | Breast cancer | IC50 : 3.2 ± 0.4 µM |
| dbacp02637 | Decoralin | SLLSLIRKLI | Solitary eumenine wasp | Mediate necrosis | MTT assay | MCF-7 | Breast cancer | IC50 : 12.5 μmolL−1 |
| dbacp02644 | Defensin-like protein (Sesquin) | KTCENLADTY | Yard-Long bean | Anti-proliferative action | MTT assay | M1 | Breast cancer | MIC : 0.125 μg/ml |
| dbacp02654 | Dermaseptin PS4 | MDILKKSIFLVLFLGLVSLSICEEEKRENEDEEKQEDDEQSEEKRALWKTLLKHVGKAAGKAALNAVTDMVNQGEQ | Sauvage's leaf frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | MCF-7 | Breast cancer | MIC : 10−9 to 10−4 M |
| dbacp02660 | Dermaseptin-B3 | ALWKnMLKGIGKLAGQAALGAVKTLVGA | South American frog, Giant leaf frog | Apoptosis inducing | Thymidine Incorporation assay | MCF-7 | Breast cancer | Not found |
| dbacp02661 | Dermaseptin-B4 | ALWKDILKNVGKAAGKAVLNTVTDMVNQ | Giant leaf frog | Apoptosis inducing | Thymidine Incorporation assay | MCF-7 | Breast cancer | Not found |
| dbacp02674 | Dermaseptin-PD1 | GMWSKIKETAMAAAKEAAKAAGKTISDMIKQ | Mexican leaf frog | Destroy plasma membrane | MTT assay | U251MG | Breast cancer | IC50 : 13.43 μM |
| dbacp02677 | Dermaseptin-PD2 | GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI | Mexican leaf frog | Destroy plasma membrane | MTT assay | U251MG | Breast cancer | IC50 : 13.43 μM |
| dbacp02686 | Dermaseptin-PH | ALWKEVLKNAGKAALNEINNLV | Orange-legged leaf frog, Northern orange-legged leaf frog, South America | Cell membrane permeabilization | MTT cell proliferation assay | MDA-MB-435S | Breast cancer | IC50 : 9.94 μM |
| dbacp02689 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | MCF-7 | Breast cancer | IC50 : 17.44 - 49.51 μM |
| dbacp02694 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Breast cancer | IC50 : 7.44 μM |
| dbacp02699 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Breast cancer | IC50 : 49.51 μM |
| dbacp02704 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Breast cancer | IC50 : 25.51 μM |
| dbacp02709 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Breast cancer | IC50 : 21.78 μM |
| dbacp02714 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Breast cancer | IC50 : 28.95 μM |
| dbacp02719 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Breast cancer | IC50 : 51.04 μM |
| dbacp02730 | Dermaseptin-PS4 | ALWKTLLKHVGKAAGKAALNAVTDMVNQ | Waxy monkey tree frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | MCF-7 | Breast cancer | MIC : 10−9 to 10−4 M |
| dbacp02732 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | MCF-7 | Breast cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02737 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | MCF-7 | Breast cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02742 | Dermaseptins B2 | GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV-NH2 | Giant leaf frog | Interact with the lipids of the plasma membrane | In vitro proliferation assay, Lactate dehydrogenase (LDH)-release assay | PC3 | Human breast cancer | GI50 : 2.17 ± 0.48 μM |
| dbacp02745 | Dex-(KW)3 | KWKWKW | Synthetic | Cell membrane disruption | MTT/MTS assay | MCF-7 | Breast cancer | At 10 µM 35-40% viablity |
| dbacp02749 | Di-PST13-RK-C | KKKFPWWWPFKKKCKKKFPWWWPFKKKC | Derivative of tritrpticin | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 17 µg/ml |
| dbacp02751 | Di-PST13-RK-K | KKKFPWWWPFKKKKKKFPWWWPFKKKK | Derivative of tritrpticin | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 10 µg/ml |
| dbacp02759 | Dimer of peptide-paclitaxel conjugate | (K-Aib-C(CH2CO-2'-Pac))2 | Synthetic peptide paclitaxel conjugate | Not specified | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 0.62 nM |
| dbacp02815 | DRS B3 | ALWKnMLKGIGKLAGQAALGAVKTLVGA | Dermaseptins B | Apoptosis inducing | Thymidine incorporation assay | MCF-7 | Breast cancer | Cytotoxicity :12 µM |
| dbacp02816 | DRS B4 | ALWKDILKNVGKAAGKAVLNTVTDMVNQ | Dermaseptins B | Apoptosis inducing | Thymidine incorporation assay | MCF-7 | Breast cancer | Cytotoxicity :15 µM |
| dbacp02817 | DRS S1 | ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ | Dermaseptins B | Apoptosis inducing | Thymidine incorporation assay | MCF-7 | Breast cancer | Not found |
| dbacp02826 | EGFR-lytic | YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK | Synthetic Peptide | Cell membrane lysis | ELISA | MDA-MB-231 | Breast cancer | IC50 : 0.12 µM |
| dbacp02827 | EGFR-lytic | YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK | Synthetic Peptide | Cell membrane lysis | ELISA | MDA-MB-231 | Breast cancer | IC50 : 0.46 µM |
| dbacp02829 | Elastin derived peptide | VGVAPG | Elastin derived | Apoptosis inducing | Cell viability assay | MCF-7 | Breast cancer | Not found |
| dbacp02932 | Figainin 1 | FIGTLIPLALGALTKLFK | Chaco tree frog | Membrane disruption and cell lysis | MTT/MTS assay | HeLa | Breast cancer | IC50 :11.1 µM |
| dbacp02934 | Figainin 1 | MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG | Chaco tree frog | Anti-proliferative action | MTT/MTS assay | NIH/3T3 | Breast cancer | IC50 : 13 µM |
| dbacp02937 | Figainin 1 | MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG | Chaco tree frog | Anti-proliferative action | MTT/MTS assay | B16F10 | Breast cancer | IC50 : 10.5 µM |
| dbacp02940 | Figainin 1 | MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG | Chaco tree frog | Anti-proliferative action | MTT/MTS assay | MCF | Breast cancer | IC50 : 13.7 µM |
| dbacp02943 | Figainin 1 | MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG | Chaco tree frog | Anti-proliferative action | MTT/MTS assay | HeLa | Breast cancer | IC50 : 11.1 µM |
| dbacp02948 | Figainin 1 | FIGTLIPLALGALTKLFK | Skin secretions, Chaco tree frog, South America | Membrane disruption | MTT/MTS assay | HeLa | Breast cancer | IC50 : 11.1 µM |
| dbacp02952 | Figainin 2 | MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ | Chaco tree frog | Necrosis; Apoptosis | MTT/MTS assay | B16F10 | Breast cancer | IC50 : 12.8 µM |
| dbacp02954 | Figainin 2 | MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ | Chaco tree frog | Necrosis; Apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 15.3 µM |
| dbacp03028 | Gageostatin A | ELLVDLL | Bacillus subtilis | Perturbation of the cell membrane | Sulforhodamine B (SBR) assay | MDA-MB-231 | Breast cancer | GI50 : 4.6–19.6 μg/mL |
| dbacp03034 | Galaxamide derivative (Compound 3) | cyclo(WnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Breast cancer | IC50 : 3.98 ± 0.71 μg/mL |
| dbacp03035 | Galaxamide derivative (Compound 3) | cyclo(WnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 1.72 ± 0.85 μg/mL |
| dbacp03036 | Galaxamide derivative (Compound 3) | cyclo(WnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HeLa | Breast cancer | IC50 : 5.32 ± 0.42 μg/mL |
| dbacp03037 | Galaxamide derivative (Compound 3) | cyclo(WnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MD-MBA-231 | Breast cancer | IC50 :3.51 ± 1.32 μg/Ml |
| dbacp03038 | Galaxamide derivative Compound 1 | cyclo(FnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Breast cancer | IC50 : 6.25 ± 1.03 μg/mL |
| dbacp03039 | Galaxamide derivative Compound 1 | cyclo(FnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 4.76 ± 1.36 μg/mL |
| dbacp03040 | Galaxamide derivative Compound 1 | cyclo(FnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HeLa | Breast cancer | IC50 : 13.22 ± 1.12 μg/mL |
| dbacp03041 | Galaxamide derivative Compound 1 | cyclo(FnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MD-MBA-231 | Breast cancer | IC50 : 5.83 ± 0.45 μg/M |
| dbacp03042 | Galaxamide derivative Compound 2 | cyclo(NAl-nMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Breast cancer | IC50 : 8.42 ± 1.82 μg/mL |
| dbacp03043 | Galaxamide derivative Compound 2 | cyclo(NAl-nMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 3.16 ± 0.92 μg/mL |
| dbacp03044 | Galaxamide derivative Compound 2 | cyclo(NAl-nMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HeLa | Breast cancer | IC50 : 6.43 ± 1.20 μg/mL |
| dbacp03045 | Galaxamide derivative Compound 2 | cyclo(NAl-nMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | MD-MBA-231 | Breast cancer | IC50 : 4.48 ± 2.24 μg/mL |
| dbacp03061 | GGN6 | FLPLLAGLAANFLPTIICKISYKC | Skin of a Korean frog, wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 4.88 µg/ml |
| dbacp03122 | Gomesin | ECRRLCYKQRCVTYCRGR | Hemocytes, Tarantula spider sp. | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp03123 | Gomesin | QCRRLCYKQRCVTYCRGR | Hemocytes, Tarantula spider sp. | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp03132 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 3.8 ± 0.3 μM |
| dbacp03137 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 67.0 ± 5.0 μM |
| dbacp03142 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 3.7 ± 0.2 μM |
| dbacp03147 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 49.9 ±16.6 μM |
| dbacp03152 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 54.1 ± 5.0 μM |
| dbacp03155 | GR01 | c[CRKDC]Disulfidebridge | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp03160 | GR16 | c[KRKDF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp03165 | GR35 | c[KRAAF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Breast cancer | Not found |
| dbacp03292 | HECI | TVLRGCWTFSFPPKPCI | Hylarana erythraea | Cell membrane disintegration | MTT anti-proliferation assay | MCF-7 | Breast cancer | MIC : 1µM |
| dbacp03343 | Human placenta hydrolysate (HPH) | NA | Human | Not specified | Not specified | BT-474 | Breast cancer | IC50 : 1.3-2.8 mg/ml |
| dbacp03353 | Hymenochirin-1B | KLSPETKDNLKKVLKGAIKGAIVAKMV | Zaire dwarf clawed frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay | MDA-MB-231 | Breast cancer | LC50 : 9.0 ± 0.3 μM |
| dbacp03367 | Ichthyophthirius multifiliis (strain G5) B4 | LKKLFKKILKYL | White spot disease (strain G5) B4 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | MCF-7 | Breast cancer | MIC : 5 μM |
| dbacp03368 | Ichthyophthirius multifiliis (strain G5) B4 | LKKLFKKILKYL | White spot disease (strain G5) B4 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | K562 | Breast cancer | MIC : 5 μM |
| dbacp03369 | Ichthyophthirius multifiliis (strain G5) B8 | LKKLFKKILKY | White spot disease (strain G5) B8 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | MCF-7 | Breast cancer | MIC : 7 μM |
| dbacp03370 | Ichthyophthirius multifiliis (strain G5) B8 | LKKLFKKILKY | White spot disease (strain G5) B8 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | K562 | Breast cancer | MIC : 7 μM |
| dbacp03371 | Ichthyophthirius multifiliis BP100 | KKLFKKILKYL | White spot disease BP100 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | MCF-7 | Breast cancer | MIC : 25 μM |
| dbacp03372 | Ichthyophthirius multifiliis BP100 | KKLFKKILKYL | White spot disease BP100 | Apoptosis inducing; Penetration of the cell membrane | MTT assay | K562 | Breast cancer | MIC : 25 μM |
| dbacp03379 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | MDA-MB-231 | Breast cancer | IC50 : 5.7 µMol/L |
| dbacp03486 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Breast cancer | IC50 : 8.64μM |
| dbacp03491 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Breast cancer | IC50 : 18.51μM |
| dbacp03496 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Breast cancer | IC50 : 9.88μM |
| dbacp03501 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Breast cancer | IC50 : 9.97μM |
| dbacp03506 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Breast cancer | IC50 : 11.17μM |
| dbacp03511 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Breast cancer | IC50 : 48.80μM |
| dbacp03550 | L1 | PEWFKCRRWQWRMKKLGA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : > 404 µM |
| dbacp03553 | L10 | PAARKAFRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 20 µM |
| dbacp03556 | L11 | PAARKAARWAWRMLKKGA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 75 µM |
| dbacp03559 | L12 | PAWRKAFRWAKRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 10 µM |
| dbacp03562 | L13 | PAWRKAFRKAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 12 µM |
| dbacp03565 | L14 | PAWRKARRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 141 µM |
| dbacp03568 | L15 | PAWRKARRWARRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 92 µM |
| dbacp03572 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 83.6 µMo/L |
| dbacp03580 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 83.6 µMo/L |
| dbacp03587 | L2 | PAWFKARRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : >254 µM |
| dbacp03591 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 70.8 µMo/L |
| dbacp03598 | L3 | PAWRKAFRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 18 µM |
| dbacp03605 | L4 | PAWFKARRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 16 µM |
| dbacp03608 | L5 | PAWRKAFRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 8 µM |
| dbacp03611 | L6 | PAWRKAFRWAARMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 12 µM |
| dbacp03615 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 62.3 µMo/L |
| dbacp03623 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >83.6 µMo/L |
| dbacp03630 | L7 | PAWRKAFRAAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 11 µM |
| dbacp03633 | L8 | PAWAKAFRAAARMKLKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 87 µM |
| dbacp03636 | L9 | PAWRKAARWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 :32 µM |
| dbacp03705 | Latarcin 2a | GLFGKLIKKFGRKAISYAVKKARGKH | Central Asian spider | Membrane disruption | LDH leakage assay | Breast tumor cell line | Breast cancer | Not found |
| dbacp03723 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog | Cell Apoptosis | MTT assay | U251MG | Breast cancer | IC50 : 2.32 μM |
| dbacp03727 | LFB | GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC | The Fujian Large Headed Frog, China, Asia | Cell Apoptosis | MTT assay | U251MG | Breast cancer | IC50 : 2.32 μM |
| dbacp03731 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | MT-1 | Breast cancer | IC50 : > 160 µM |
| dbacp03753 | LHRH–BH3 peptide luteinizing hormone-releasing hormone (LHRH) | QHWSYGLRPGMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Inducing apoptosis | Cytotoxicity assay, MTT assay | MCF-7 | Human breast cancer | Not found |
| dbacp04106 | linear (RW)4-Dox | RWRWRWRW | Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP | Inhibition of the cell proliferation | MTT/MTS assay | MDA-MB-468 | Breast cancer | 60-74% anti-proliferative activity at 1 µM |
| dbacp04130 | LK1 (Temporin-1CEa Analog peptide) | FVDLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MCF-7 | Breast cancer | IC50 : 20.97 µM |
| dbacp04131 | LK1 (Temporin-1CEa Analog peptide) | FVDLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | Bcap-37 | Breast cancer | IC50 : 18.7 µM |
| dbacp04132 | LK1 (Temporin-1CEa Analog peptide) | FVDLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MDA-MB-231 | Breast cancer | IC50 : 66.4µM |
| dbacp04133 | LK2(5) (Temporin-1CEa Analog peptide) | FKDLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MCF-7 | Breast cancer | IC50 : 44.7 µM |
| dbacp04134 | LK2(5) (Temporin-1CEa Analog peptide) | FKDLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | Bcap-37 | Breast cancer | IC50 : 83.49 µM |
| dbacp04135 | LK2(5) (Temporin-1CEa Analog peptide) | FKDLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MDA-MB-231 | Breast cancer | IC50 : 894.7 µM |
| dbacp04136 | LK2(6) (Temporin-1CEa Analog peptide) | FVKLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MCF-7 | Breast cancer | IC50 : 15.54 µM |
| dbacp04137 | LK2(6) (Temporin-1CEa Analog peptide) | FVKLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | Bcap-37 | Breast cancer | IC50 : 18.9 µM |
| dbacp04138 | LK2(6) (Temporin-1CEa Analog peptide) | FVKLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MDA-MB-231 | Breast cancer | IC50 : 85.41 µM |
| dbacp04139 | LK2(6)A(L) (Temporin-1CEa Analog peptide) | FVKLKKILNIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MCF-7 | Breast cancer | IC50 : 9.01 µM |
| dbacp04140 | LK2(6)A(L) (Temporin-1CEa Analog peptide) | FVKLKKILNIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | Bcap-37 | Breast cancer | IC50 : 10.52 µM |
| dbacp04141 | LK2(6)A(L) (Temporin-1CEa Analog peptide) | FVKLKKILNIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MDA-MB-231 | Breast cancer | IC50 : 34.74 µM |
| dbacp04142 | LK2(6)AN(2L) (Temporin-1CEa Analog peptide) | FVKLKKILNIILSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MCF-7 | Breast cancer | IC50 : 11 µM |
| dbacp04143 | LK2(6)AN(2L) (Temporin-1CEa Analog peptide) | FVKLKKILNIILSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | Bcap-37 | Breast cancer | IC50 : 9.39 µM |
| dbacp04144 | LK2(6)AN(2L) (Temporin-1CEa Analog peptide) | FVKLKKILNIILSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MDA-MB-231 | Breast cancer | IC50 : 41.55 µM |
| dbacp04145 | LK3 (Temporin-1CEa Analog peptide) | FKKLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MCF-7 | Breast cancer | IC50 : 27.72 µM |
| dbacp04146 | LK3 (Temporin-1CEa Analog peptide) | FKKLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | Bcap-37 | Breast cancer | IC50 : 25.04 µM |
| dbacp04147 | LK3 (Temporin-1CEa Analog peptide) | FKKLKKIANIINSIFKK | Synthetic construct | Cell membrane disintegration | MTT-assay | MDA-MB-231 | Breast cancer | IC50 : 224.8 µM |
| dbacp04148 | LL 37 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | Also known human cathelicidin | Plasma membrane perturbations | MTT/MTS assay | MCF-7 | Breast cancer | LC50 : 21 at 100 µM |
| dbacp04297 | LTX-302 | WKKW-Dip-KKWK | Synthetic peptide | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 73 ± 2 µM |
| dbacp04300 | LTX-315 | KKWWKKW-Dip-K | Synthetic peptide | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 31 ± 3 µM |
| dbacp04306 | LTX-318 | OOW-Dip-OOWWO | Synthetic peptide | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 216 ± 36 µM |
| dbacp04311 | Lunasin | SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD | Soyabean | Cell membrane degradation | TUNEL DNA fragmentation assay | MCF-7 | Breast cancer | Not found |
| dbacp04353 | Lytic | KLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | MDA-MB-231 | Breast cancer | IC50 : 18.5 µMol/L |
| dbacp04354 | Lytic | KLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | BT-474 | Breast cancer | IC50 : 34.5 µM |
| dbacp04355 | Lytic | KLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | T-47D | Breast cancer | IC50 : 14.1 µM |
| dbacp04356 | Lytic | KLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | SK-BR-3 | Breast cancer | IC50 : 25.7 µM |
| dbacp04357 | Lytic | KLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | MDA-MB-231 | Breast cancer | IC50 : 27.0 µM |
| dbacp04358 | Lytic | KLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | BT-20 | Breast cancer | IC50 : 20.0 µM |
| dbacp04359 | Lytic | KLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | ZR75-1 | Breast cancer | IC50 : 19.4 µM |
| dbacp04452 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Fringed Tree Frog, Australia | Disruption of cancer membrane integrity | Not specified | Not specified | Breast cancer | MIC : 1 – 100 µg/ml |
| dbacp04461 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Fringed Tree Frog, Australia | Disruption of cancer cell membrane integrity | Not specified | Not specified | Breast cancer | MIC : 1 – 100 µg/ml |
| dbacp04471 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Fringed Tree Frog, Australia | Disruption of cancer cell membrane integrity | Not specified | Not specified | Breast cancer | IC50 : 10−5 - 10−6 M |
| dbacp04495 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : >200 µg/ml |
| dbacp04513 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : 49 µg/ml |
| dbacp04523 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : 37 µg/ml |
| dbacp04539 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : 42 µg/ml |
| dbacp04542 | Malanin chain A | DYPKLTFTTS | Plant sources | Inducing apoptosis | MTT assay | PC-12 | Breast cancer | IC50 : 7.71 ± 0.24 nM |
| dbacp04548 | Malanin chain B | DETCTDEEFN | Plant sources | Inducing apoptosis | MTT assay | PC-12 | Breast cancer | IC50 : 7.71 ± 0.24 nM |
| dbacp04553 | MAP-04-03 | KWLRRVWRWWR | Analogs of Ixosin-B amide | Disrupting the integrity of cell membrane | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability : >80% at 25 µM |
| dbacp04554 | MAP-04-03 | KWLRRVWRWWR | Analogs of Ixosin-B amide | Disrupting the integrity of cell membrane | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability : ~50% at 50 µM |
| dbacp04555 | MAP-04-03 | KWLRRVWRWWR | Analogs of Ixosin-B amide | Disrupting the integrity of cell membrane | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability : <40% at 75 µM |
| dbacp04556 | MAP-04-03 | KWLRRVWRWWR | Analogs of Ixosin-B amide | Disrupting the integrity of cell membrane | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability : >20% at 100 µM |
| dbacp04557 | MAP-04-03 | KWLRRVWRWWR | Analogs of Ixosin-B amide | Disrupting the integrity of cell membrane | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability : ~100% at 25 µM |
| dbacp04558 | MAP-04-03 | KWLRRVWRWWR | Analogs of Ixosin-B amide | Disrupting the integrity of cell membrane | MTT/MTS assay | MCF-7 | Breast cancer | IC50 :61.5 µM |
| dbacp04559 | MAP-04-04 | KRLRRVWRRWR | Analogs of Ixosin-B amide | Disrupting the integrity of cell membrane | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability : > 80% at 50 µM |
| dbacp04560 | MAP-04-04 | KRLRRVWRRWR | Analogs of Ixosin-B amide | Disrupting the integrity of cell membrane | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability : > 80% at 75 µM |
| dbacp04561 | MAP-04-04 | KRLRRVWRRWR | Analogs of Ixosin-B amide | Disrupting the integrity of cell membrane | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability : > 80% at 100 µM |
| dbacp04577 | Mastoparan-C | LNLKALLAVAKKIL | European hornet | Apoptosis | MTT assay | MCF-7 | Human Breast cancer | IC50 : 1.4 μM |
| dbacp04579 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MDA-MB-435S | Breast cancer | MIC : 6.26 - 36.65 μM |
| dbacp04582 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MCF-7 | Breast cancer | MIC : 6.26 - 36.65 μM |
| dbacp04585 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MDA-MB-435S | Breast cancer | IC50 : < 4 μM |
| dbacp04588 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MCF-7 | Breast cancer | IC50 : < 4 μM |
| dbacp04632 | MCL-1, BH3 (208-228) | KALETLRRVGDGVQRNHETAF | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | Not specified | Not found | Breast cancer | Not found |
| dbacp04713 | mt_E17L/L22 W/P27A | LTFSDWWKLLAE | MDM3 | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 15.1 µM |
| dbacp04714 | mt_L22 W/P27A | ETFSDWWKLLAE | MDM2 | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 16.3 µM |
| dbacp04715 | mt_S20A/L22 W/P27A | ETFADWWKLLAE | MDM5 | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 8.7 µM |
| dbacp04716 | mt_T18S/L22 W/P27A | ESFSDWWKLLAE | MDM4 | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 27 µM |
| dbacp04730 | N-1 | WKLFKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 9.5 µM |
| dbacp04733 | N-2 | FKLFKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 11 µM |
| dbacp04736 | N-3 | KWFKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 17 µM |
| dbacp04739 | N-3L | WFKKIPKFLHLLKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 5 µM |
| dbacp04742 | N-4 | WFKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 32 µM |
| dbacp04745 | N-4L | WKKIPKFLHLLKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 5 µM |
| dbacp04748 | N-5 | WKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : < 100 µM |
| dbacp04751 | N-5L | WKKIPKFLHLLKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 :17 µM |
| dbacp04909 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 5% Cytotoxic at 5 µM |
| dbacp04910 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 5% Cytotoxic at 10 µM |
| dbacp04911 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 30-35% Cytotoxic at 25 µM |
| dbacp04912 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 60% Cytotoxic at 50 µM |
| dbacp04913 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 5-10% Cytotoxic at 5 µM |
| dbacp04914 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 10% Cytotoxic at 10 µM |
| dbacp04915 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 30-35% Cytotoxic at 25 µM |
| dbacp04916 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 60% Cytotoxic at 50 µM |
| dbacp04917 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 30% Cytotoxic at 5 µM |
| dbacp04918 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 50% Cytotoxic at 10 µM |
| dbacp04919 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 70% Cytotoxic at 25 µM |
| dbacp04920 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 80-85% Cytotoxic at 50 µM |
| dbacp04921 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 30% Cytotoxic at 5 µM |
| dbacp04922 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 40-50% Cytotoxic at 10 µM |
| dbacp04923 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 60-70% Cytotoxic at 25 µM |
| dbacp04924 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 80-85% Cytotoxic at 50 µM |
| dbacp04925 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 15-20% Cytotoxic at 5 µM |
| dbacp04926 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 40-50% Cytotoxic at 10 µM |
| dbacp04927 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 80% Cytotoxic at 25 µM |
| dbacp04928 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 85-90% Cytotoxic at 50 µM |
| dbacp04929 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MCF-7 | Breast cancer | 70% Cytotoxic at 50 µM |
| dbacp04930 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MCF-7-TX400 | Breast cancer | 60-70% Cytotoxic at 50 µM |
| dbacp04931 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL-NH2 | PseudopWinter flounder | Cell membrane damage | MTT/MTS assay | MCF-7-TX400 | Breast cancer | 60-70% Cytotoxic at 50 µM |
| dbacp04932 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 5% Cytotoxic at 5 µM |
| dbacp04933 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 5% Cytotoxic at 10 µM |
| dbacp04934 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 30-35% Cytotoxic at 25 µM |
| dbacp04935 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 60% Cytotoxic at 50 µM |
| dbacp04936 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 5-10% Cytotoxic at 5 µM |
| dbacp04937 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 10% Cytotoxic at 10 µM |
| dbacp04938 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 30-35% Cytotoxic at 25 µM |
| dbacp04939 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 60% Cytotoxic at 50 µM |
| dbacp04940 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 30% Cytotoxic at 5 µM |
| dbacp04941 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 50% Cytotoxic at 10 µM |
| dbacp04942 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 70% Cytotoxic at 25 µM |
| dbacp04943 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 80-85% Cytotoxic at 50 µM |
| dbacp04944 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 30% Cytotoxic at 5 µM |
| dbacp04945 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 40-50% Cytotoxic at 10 µM |
| dbacp04946 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 60-70% Cytotoxic at 25 µM |
| dbacp04947 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 80-85% Cytotoxic at 50 µM |
| dbacp04948 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 15-20% Cytotoxic at 5 µM |
| dbacp04949 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 40-50% Cytotoxic at 10 µM |
| dbacp04950 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 80% Cytotoxic at 25 µM |
| dbacp04951 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 85-90% Cytotoxic at 50 µM |
| dbacp04952 | NRC-03 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MCF-7 | Breast cancer | 70% Cytotoxic at 50 µM |
| dbacp04954 | NRC-07 | GRRKRKWLRRIGKGVKIIGGAALDHL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | ~0% Cytotoxic at 5 µM |
| dbacp04955 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 5% Cytotoxic at 10 µM |
| dbacp04956 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 20-30% Cytotoxic at 25 µM |
| dbacp04957 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 40-50% Cytotoxic at 50 µM |
| dbacp04958 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | ~0% Cytotoxic at 5 µM |
| dbacp04959 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 10% Cytotoxic at 10 µM |
| dbacp04960 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 20% Cytotoxic at 25 µM |
| dbacp04961 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 40-50% Cytotoxic at 50 µM |
| dbacp04962 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | ~0% Cytotoxic at 5 µM |
| dbacp04963 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 20% Cytotoxic at 10 µM |
| dbacp04964 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 70-80% Cytotoxic at 25 µM |
| dbacp04965 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 80-85% Cytotoxic at 50 µM |
| dbacp04966 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 10% Cytotoxic at 5 µM |
| dbacp04967 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 50% Cytotoxic at 10 µM |
| dbacp04968 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 80% Cytotoxic at 25 µM |
| dbacp04969 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 80-90% Cytotoxic at 50 µM |
| dbacp04970 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 30-40% Cytotoxic at 5 µM |
| dbacp04971 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 60-70% Cytotoxic at 10 µM |
| dbacp04972 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 80-90% Cytotoxic at 25 µM |
| dbacp04973 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 85-90% Cytotoxic at 50 µM |
| dbacp04974 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MCF-7 | Breast cancer | 70% Cytotoxic at 50 µM |
| dbacp04975 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MCF-7-TX400 | Breast cancer | 60-70% Cytotoxic at 50 µM |
| dbacp04976 | NRC-07 | RWGKWFKKATHVGKHVGKAALTAYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 80% Cytotoxic at 25 µM |
| dbacp04977 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | ~5% Cytotoxic at 10 µM |
| dbacp04978 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 10% Cytotoxic at 25 µM |
| dbacp04979 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-231 | Breast cancer | 10-15% Cytotoxic at 50 µM |
| dbacp04980 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | ~0% Cytotoxic at 5 µM |
| dbacp04981 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | ~0% Cytotoxic at 10 µM |
| dbacp04982 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 10% Cytotoxic at 25 µM |
| dbacp04983 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | T-47D | Breast cancer | 10-15% Cytotoxic at 50 µM |
| dbacp04984 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 10% Cytotoxic at 5 µM |
| dbacp04985 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 10% Cytotoxic at 10 µM |
| dbacp04986 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 10-15% Cytotoxic at 25 µM |
| dbacp04987 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | SKBR-3 | Breast cancer | 15-20% Cytotoxic at 50 µM |
| dbacp04988 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | ~5% Cytotoxic at 5 µM |
| dbacp04989 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | ~5% Cytotoxic at 10 µM |
| dbacp04990 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 5% Cytotoxic at 25 µM |
| dbacp04991 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MDA-MB-468 | Breast cancer | 10-15% Cytotoxic at 50 µM |
| dbacp04992 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | ~0% Cytotoxic at 5 µM |
| dbacp04993 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | ~0% Cytotoxic at 10 µM |
| dbacp04994 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 5-10% Cytotoxic at 25 µM |
| dbacp04995 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | 4T1 | Breast cancer | 20% Cytotoxic at 50 µM |
| dbacp04996 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MCF-7 | Breast cancer | 0% Cytotoxic at 50 µM |
| dbacp04997 | NRC-13 | GWRTLLKKAEVKTVGKLALKHYL | Skin mucous secretion of winter flounder | Cell membrane damage | MTT/MTS assay | MCF-7-TX400 | Breast cancer | ~5% Cytotoxic at 50 µM |
| dbacp05000 | NuBCP-9 (DR8) | FSRSLHSLLRRRRRRRR | Not found | Inducing apoptosis | XTT assat | MCF-7 | Breast cancer | IC50 : 7.11 μM |
| dbacp05023 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 15.8 µMo/L |
| dbacp05035 | p120RasGAP (317-326) | WMWVTNLRTD | Not found | Inducing apoptosis | Luciferase assay | HeLa | Breast cancer | Not found |
| dbacp05037 | P160 | VPWMEPAYQRFL | Not found | Apoptosis inducing | MTT cytotoxicity assay | MCF-7 | Breast cancer | IC50 : 14.2 ± 1.5 μM |
| dbacp05048 | P18 | KWKFKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 8 µM |
| dbacp05078 | p53-C terminal peptide | GSRAHSSHLKSKKGQSTSRHKK | Not found | Inducing apoptosis | Annexin V-FITC Binding assay | MDA-MB-468 | Breast cancer | Not found |
| dbacp05079 | p53-C terminal peptide | GSRAHSSHLKSKKGQSTSRHKK | Not found | Inducing apoptosis | Annexin V-FITC Binding assay | MDA-MB-231 | Breast cancer | Not found |
| dbacp05080 | p53-C terminal peptide | GSRAHSSHLKSKKGQSTSRHKK | Not found | Inducing apoptosis | Annexin V-FITC Binding assay | MCF-7 | Breast cancer | Not found |
| dbacp05081 | p53-C terminal peptide | GSRAHSSHLKSKKGQSTSRHKK | Not found | Inducing apoptosis | Annexin V-FITC Binding assay | MCF10-2A | Breast cancer | Not found |
| dbacp05103 | PA10 | RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05104 | PA10 | RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05105 | PA10 | RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05106 | PA10 | RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05107 | PA15 | RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05108 | PA15 | RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05109 | PA15 | RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05110 | PA15 | RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05111 | PA2 | RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05112 | PA2 | RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05113 | PA2 | RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05114 | PA2 | RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05115 | PA3 | RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05116 | PA3 | RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05117 | PA3 | RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05118 | PA3 | RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05119 | PA38 | RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05120 | PA38 | RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05121 | PA38 | RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05122 | PA38 | RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05123 | PA49 | RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MDA-MB231 | Breast cancer | MIC : 10 μM |
| dbacp05124 | PA49 | RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | HCC1806 | Breast cancer | MIC : 10 μM |
| dbacp05125 | PA49 | RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | 184B5 | Breast cancer | MIC : 10 μM |
| dbacp05126 | PA49 | RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH | Synthetic construct | Cell proliferation inhibition; Cell penetration; Apoptosis | Cell viability assay | MCF10A | Breast cancer | MIC : 10 μM |
| dbacp05250 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 70 µM |
| dbacp05255 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : > 70 µM |
| dbacp05256 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 70 µM |
| dbacp05261 | Pep27 anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 55 µM |
| dbacp05266 | Pep27 anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : < 10 µM |
| dbacp05271 | Pep27 anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 38 µM |
| dbacp05276 | Pep27 anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : 29 µM |
| dbacp05281 | Pep27 anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Not found | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | IC50 : > 70 µM |
| dbacp05286 | Pep27anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 55 µM |
| dbacp05291 | Pep27anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : < 10 µM |
| dbacp05296 | Pep27anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 38 µM |
| dbacp05301 | Pep27anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 29 µM |
| dbacp05306 | Pep27anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >70 µM |
| dbacp05400 | Peptide from Lentinus Squarrosulus | RYGFTEVAGNFQQHNFGRG | Plant sources | Inducing apoptosis | MTT assay | H460 | Breast cancer | Not found |
| dbacp05401 | Peptide from Lentinus Squarrosulus | RYGFTEVAGNFQQHNFGRG | Plant sources | Inducing apoptosis | MTT assay | DPCs | Breast cancer | Not found |
| dbacp05402 | Peptide from Lentinus Squarrosulus | RYGFTEVAGNFQQHNFGRG | Plant sources | Inducing apoptosis | MTT assay | HK-2 | Breast cancer | Not found |
| dbacp05439 | Peptide-20 | CSSRTMHHC | Synthetic Peptide | Inducing apoptosis | MTT/MTS assay | MDA-MB-231 | Breast cancer | At 100 µM 55% viablity |
| dbacp05484 | Pexiganan | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Plasma membrane perturbations | MTT/MTS assay | MCF-7 | Breast cancer | LC50 : 8 at 100 µM |
| dbacp05532 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB231 | Breast cancer | IC50 : approx. 0.29 µM |
| dbacp05533 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB435s | Breast cancer | IC50 : approx. 0.29 µM |
| dbacp05534 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MCF-7 | Breast cancer | IC50 : approx. 0.29 µM |
| dbacp05543 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB231 | Breast cancer | IC50 : approx. 0.50 µM |
| dbacp05544 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MB435s | Breast cancer | IC50 : approx. 0.50 µM |
| dbacp05545 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | MCF-7 | Breast cancer | IC50 : approx. 0.50 µM |
| dbacp05552 | Phylloseptin-PHa | FLSLIPAAISAVSALANHF | Northern orange-legged leaf frog | Disruption of the membrane | MTT assay, Lactate dehydrogenase (LDH) assay | MCF-7 | Human breast cancer | LD50 : < 5 µM |
| dbacp05563 | Piscidin 1 | FFHHIFRGIVHVGKTIHRLVTG | Hybrid striped bass (Striped bass x White bass) | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp05564 | Piscidin 1 | FFHHIFRGIVHVGKTIHRLVTG | Mainly mast cells, gill, skin, intestine, spleen, and anterior kidney, hybrid striped bass (Striped bass x White bass) | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp05589 | Polybia-CP | ILGTILGLLKSL | Neotropical social wasp, Swarm-founding polistine wasp | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp05590 | Polybia-CP (Pol-CP-NH2) (Polybia chemotactic peptide) | ILGTILGLLKSL | Neotropical social wasp, Swarm-founding polistine wasp | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp05591 | Polybia-mastoparan-I | IDWKKLLDAAKQIL | Neotropical social wasp, Swarm-founding polistine wasp | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp05592 | Polybia-mastoparan-I | IDWKKLLDAAKQIL | Neotropical social wasp, Swarm-founding polistine wasp | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp05593 | Polybia-MPI | IDWKKLLDAAKQIL | Venom, social wasp | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp05594 | Polybia-MPI | IDWKKLLDAAKQIL | Social wasp | Not specified | Not specified | Not found | Breast cancer | Not found |
| dbacp05595 | Polybia-MPI | IDWKKLLDAAKQIL | Venom, social wasp | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp05674 | Protein S100-A8 | MLTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLKKLLETECPQYIRKKGADVWFKELDINTDGAVNFQEFLILVIKMGVAAHKKSHEESHKE | Human | Apoptosis inducing | MTT/MTS assay | MM46 | Breast cancer | IC50 : 10 µM |
| dbacp05695 | PST13-RK | KKKFPWWWPFKKK | Derivative of tritrpticin | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 80 µg/ml |
| dbacp05712 | PTP1 | LLAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >100 µg/ml |
| dbacp05717 | PTP2 | FAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >100 µg/ml |
| dbacp05722 | PTP4 | FLKLLKKLAAKFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 18.1 µg/ml |
| dbacp05727 | PTP5 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.43 µg/ml |
| dbacp05732 | PTP6 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 17.56 µg/ml |
| dbacp05737 | PTP7 | FLGALFKALSKLL | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.25 µg/ml |
| dbacp05742 | PTP8 | FLKLLAGLLKNFA | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 32.23 µg/ml |
| dbacp05795 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Breast cancer | IC50 : 843.40 µM |
| dbacp05798 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Breast cancer | IC50 : 843.40 µM |
| dbacp05802 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Breast cancer | IC50 : 872.70 µM |
| dbacp05806 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Breast cancer | IC50 : 283.90 µM |
| dbacp05810 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Breast cancer | IC50 : 104.10 µM |
| dbacp05814 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Breast cancer | IC50 : 109.30 µM |
| dbacp05818 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Breast cancer | IC50 : 588.20 µM |
| dbacp05863 | RA-V | cyclopeptideRA-V-,cyclo(YAAYAY) | Plant sources | Inducing apoptosis | MTT assay | MCF-7 | Breast cancer | Not found |
| dbacp05864 | RA-V | cyclopeptideRA-V-,cyclo(YAAYAY) | Plant sources | Inducing apoptosis | MTT assay | MDA-MB-231 | Breast cancer | Not found |
| dbacp05865 | RA-V | cyclopeptideRA-V-,cyclo(YAAYAY) | Plant sources | Inducing apoptosis | MTT assay | 4T1 | Breast cancer | Not found |
| dbacp05873 | Radical SAM domain protein | MEAVLYVTRKCNLSCGHCIVDKEDNSDLPTDKVETLASDYPIDRTILSGGEPFLHDNFEELVALVPEPTVLSNGLVLSDEEYVGENSDMLEELNGIQLSVEGKEETTDARRGEGVWDRVMEAHQNLSEIGVESYLRSTYSREMMEEVGELMEFCDAEGISLVLFPEIGKPPLSPTENASFFDYAVEKGVVVATPDFHSYIGEGGECPAARTRISVDVNGEIYPCQFNWDYCLGEVGDEWGLIESRIERFDRTEPVPRTCSRCDFANKCRGCGVADTWSGCPIARGLSHSESPSRRPLKRVQETMNTLEDVGAPRGCHGC | Uncultured archaeon | Apoptosis inducing | MTT assay | MCF-7 | Breast cancer | MIC : 42% ± 8.1 μM |
| dbacp05879 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Breast cancer | IC50 : 5.90 µM |
| dbacp05883 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Breast cancer | IC50 : 15.44 µM |
| dbacp05887 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Breast cancer | IC50 : 5.79 µM |
| dbacp05891 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Breast cancer | IC50 : 16.14 µM |
| dbacp05895 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7) | Breast cancer | IC50 : 20.19 µM |
| dbacp05899 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Breast cancer | IC50 : 79.50 µM |
| dbacp05905 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Gram-negative purple non-sulfur bacteria | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MCF-7 | Human breast cancer | IC50 : 20.19 µM |
| dbacp05907 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Skin secretions, the pickerel frog, North America | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MDA-MB-435S | Breast cancer | IC50 : 15.44 µM |
| dbacp05910 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Skin secretions, the pickerel frog, North America | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | MCF-7 | Breast cancer | IC50 : 20.19 µM |
| dbacp05942 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : >10 µM |
| dbacp05951 | RGD-La | RGDLLRHVVKILEKYL | Arg-Gly-Asp(RGD) tripeptide ana temporins | Cell membrane disintegration | MTT/MTS assay | MEC | Breast cancer | 19.76 Inhibition ratio at 50 µg/ml |
| dbacp05960 | RGD-Las | RGDLLRHVVKILSKYL | Arg-Gly-Asp(RGD) tripeptide ana temporins | Cell membrane disintegration | MTT/MTS assay | MEC | Breast cancer | 29.33 Inhibition ratio at 50 µg/ml |
| dbacp05961 | RGD-mda-7 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQKFYKL | Derived from wtmda-7/IL-24 by insertion or a glycine residue between Arg(164) and Asp(165). | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability(% of control):0.5 at concentration 4 µg/ml |
| dbacp05963 | RGD-mda-7 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQKFYKL | Derived from wtmda-7/IL-24 by insertion or a glycine residue between Arg(164) and Asp(165). | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | Apoptotic rate(%): >70% at concentration of 8 µg/ml |
| dbacp05986 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Breast cancer | IC50 : 58.18 µM |
| dbacp05990 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Breast cancer | IC50 : 179.00 µM |
| dbacp05994 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Breast cancer | IC50 : 792.60 µM |
| dbacp05998 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Breast cancer | IC50 : 278.30 µM |
| dbacp06002 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Breast cancer | IC50 : 316.90 µM |
| dbacp06006 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Breast cancer | IC50 : 1185.00 µM |
| dbacp06031 | Sclareol synthase | MSLAFNVGVTPFSGQRVGSRKEKFPVQGFPVTTPNRSRLIVNCSLTTIDFMAKMKENFKREDDKFPTTTTLRSEDIPSNLCIIDTLQRLGVDQFFQYEINTILDNTFRLWQEKHKVIYGNVTTHAMAFRLLRVKGYEVSSEELAPYGNQEAVSQQTNDLPMIIELYRAANERIYEEERSLEKILAWTTIFLNKQVQDNSIPDKKLHKLVEFYLRNYKGITIRLGARRNLELYDMTYYQALKSTNRFSNLCNEDFLVFAKQDFDIHEAQNQKGLQQLQRWYADCRLDTLNFGRDVVIIANYLASLIIGDHAFDYVRLAFAKTSVLVTIMDDFFDCHGSSQECDKIIELVKEWKENPDAEYGSEELEILFMALYNTVNELAERARVEQGRSVKEFLVKLWVEILSAFKIELDTWSNGTQQSFDEYISSSWLSNGSRLTGLLTMQFVGVKLSDEMLMSEECTDLARHVCMVGRLLNDVCSSEREREENIAGKSYSILLATEKDGRKVSEDEAIAEINEMVEYHWRKVLQIVYKKESILPRRCKDVFLEMAKGTFYAYGINDELTSPQQSKEDMKSFVF | Clary sage | Apoptotic death | Not specified | SiHa | Metastatic breast cancer | IC50 : 0.77 - 12.5μM |
| dbacp06076 | Shiva-1 | MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG | African clawed frog | Pore formation at the cytoplasmic membrane | MTT/MTS assay | BTS-30 | Breast cancer | IC50 : 56 µM |
| dbacp06118 | SK84 | SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK | Fruit fly | Cell membrane disintegration | MTS/PES colorimetric assay | HepG2 | Breast cancer | IC50 : 92 μM |
| dbacp06120 | SK84 | SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK | Fruit fly | Cell membrane disintegration | MTS/PES colorimetric assay | MCF-7 | Breast cancer | IC50 : 50 μM |
| dbacp06122 | SK84 | SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK | Fruit fly | Cell membrane disintegration | MTS/PES colorimetric assay | THP-1 | Breast cancer | IC50 : 35 μM |
| dbacp06125 | SK84 | SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK | Fruit fly | Destroying the cell membranes | Cell proliferation assay | MCF-7 | Breast cancer | MIC : 4 – 8 mM |
| dbacp06140 | SP22 | ACHWPWCHGWHSACDLPMHPMC | Not found | Inducing apoptosis | Tunnel assay | MCF-7 | Breast cancer | Not found |
| dbacp06171 | SVS-1 | KVKVKVKVpPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 8.1 ± 0.8 µM |
| dbacp06172 | SVS-1 | KVKVKVKVpPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MDA-MB-436 | Breast cancer | IC50 : 5.6 ± 0.5 µM |
| dbacp06175 | SVS-2 | KVKVKVKVPPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >100 µM |
| dbacp06176 | SVS-2 | KVKVKVKVPPTKVKVKVK | Synthetic peptide | Disruption of cell membranes | MTT/MTS assay | MDA-MB-436 | Breast cancer | IC50 : >100 µM |
| dbacp06187 | t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) | RKKRRQRRRLNLKALLAVAKKIL | Synthetic construct | Apoptosis inducing | MTT assay | MCF-7 | Human breast cancer | IC50 : 3.70 μM |
| dbacp06219 | TAT-RasGAP (317-326) From p120RasGAP | GRKKRRQRRRGGWMWVTNLRTD | Not found | Inducing apoptosis | Luciferase assay | HeLa | Breast cancer | Not found |
| dbacp06222 | Tempoprin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 70% Cell viability at 20 µM |
| dbacp06223 | Tempoprin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 45% Cell viability at 30 µM |
| dbacp06224 | Tempoprin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Cell membrane disruption | MTT/MTS assay | Bcap-37 | Breast cancer | 30 % Cell viability at 40 µM |
| dbacp06231 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | MTT/MTS assay | MDA-MB-231 | Breast cancer | 22% cell viability at 40 µM |
| dbacp06232 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | LDH leakage assay | MDA-MB-231 | Breast cancer | 61% cytotoxicity at 40 µM |
| dbacp06233 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | MTT/MTS assay | MCF-7 | Breast cancer | 61% cell viability at 40 µM |
| dbacp06234 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | LDH leakage assay | MCF-7 | Breast cancer | 32% cytotoxicity at 40 µM |
| dbacp06235 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | MTT/MTS assay | MDA-MB-231 | Breast cancer | MIC : 40 µM |
| dbacp06236 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | LDH leakage assay | MDA-MB-231 | Breast cancer | MIC : 40 µM |
| dbacp06237 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | MTT/MTS assay | MCF-7 | Breast cancer | MIC : 40 µM |
| dbacp06238 | Temporin-1CEa | FVDLKKIANIINSIF | Chinese brown frog | Membrane disruption | LDH leakage assay | MCF-7 | Breast cancer | MIC : 40 µM |
| dbacp06239 | Temporin-1CEb | ILPILSLIGGLLGK | Chinese brown frog or Asiatic grass frog, China, Asia | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp06240 | Temporin-1CEb | ILPILSLIGGLLGK | Chinese brown frog or Asiatic grass frog, China, Asia | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp06242 | Temporin-1RNa | ILPIRSLIKKLL | The black-spotted frog, Northeastern China, Asia | Disruption of membrane | Cytotoxicity assay, MTT/MTS assay | MCF 7 | Breast cancer | IC50 : 23.4 ± 5.2 µM |
| dbacp06244 | Temporin-1RNb | FLPLKKLRFGLL | The black-spotted frog, Northeastern China, Asia | Disruption of membrane | Cytotoxicity assay, MTT/MTS assay | MCF 7 | Breast cancer | IC50 : 11.4 ± 2.3 µM |
| dbacp06265 | Temporin-Las | LLRHVVKILEKYL | Temporins family | Cell membrane disintegration | MTT/MTS assay | MEC | Breast cancer | 24.15 inhibition ratio at 50 µg/ml |
| dbacp06266 | Temporin-Las | LLRHVVKILSKYL | Temporins family | Cell membrane disintegration | MTT/MTS assay | MEC | Breast cancer | 27.99 inhibition ratio at 50 µg/ml |
| dbacp06295 | Tetramer of peptide-paclitaxel conjugate | (K-Aib-C(CH2CO-2'-Pac))4 | Synthetic peptide paclitaxel conjugate | Not specified | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 0.64 nM |
| dbacp06326 | Transactivator of transcript-DV1-Bcl-2, AT-DV1-BH3 | RRRQRRKKRGGGGLGASWHRPDK | Transactivator of transcript-DV1-Bcl-2 TAT-DV1-BH3 | Apoptosis inducing | Cell viability assay, Transwell invasion assay | MDA-MB-231 | Breast cancer | Not specified |
| dbacp06327 | Transactivator of transcript-DV1-Bcl-2, AT-DV1-BH3 | RRRQRRKKRGGGGLGASWHRPDK | Transactivator of transcript-DV1-Bcl-2 TAT-DV1-BH4 | Apoptosis inducing | Cell viability assay, Transwell invasion assay | MCF-7 | Breast cancer | Not specified |
| dbacp06329 | Transferrin receptor (TfR)-lytic hybrid peptide | THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | BT-474 | Breast cancer | IC50 : 8.8 µM |
| dbacp06330 | Transferrin receptor (TfR)-lytic hybrid peptide | THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | T-47D | Breast cancer | IC50 : 4.0 µM |
| dbacp06331 | Transferrin receptor (TfR)-lytic hybrid peptide | THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | SK-BR-3 | Breast cancer | IC50 : 6.5 µM |
| dbacp06332 | Transferrin receptor (TfR)-lytic hybrid peptide | THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | MDA-MB-231 | Breast cancer | IC50 : 7.8 µM |
| dbacp06333 | Transferrin receptor (TfR)-lytic hybrid peptide | THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | BT-20 | Breast cancer | IC50 : 4.8 µM |
| dbacp06334 | Transferrin receptor (TfR)-lytic hybrid peptide | THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | ZR75-1 | Breast cancer | IC50 : 9.3 µM |
| dbacp06348 | Trimer of peptide-paclitaxel conjugate | (K-Aib-C(CH2CO-2'-Pac))3 | Synthetic peptide paclitaxel conjugate | Not specified | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 3.00 nM |
| dbacp06350 | Tritrpticin | VRRFPWWWPFLRR | Derivative of tritrpticin | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 142 µg/ml |
| dbacp06362 | TsAP-2 | FLGMIPGLIGGLISAFK | Venom-derived cDNAlibrary of the Brazilian yellow scorpion | Not specified | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 6.4 µM |
| dbacp06370 | TsAP-S1 | FLSLIPKLVKKIIKAFK | Derivative of TsAP-1, Brazilian yellow scorpion venom peptide | Not specified | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 1.8 µM |
| dbacp06378 | TsAP-S2 | FLGMIPKLIKKLIKAFK | Derivative of TsAP-1, Brazilian yellow scorpion venom peptide | Not specified | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 1.8 µM |
| dbacp06415 | U3 | NGSIPATWASL | Date palm | Cell proliferation inhibition | MTT/MTS assay | T47D | Breast cancer | IC50 : 434.7 – 616.5 μM |
| dbacp06416 | U3 | NGSIPATWASL | Date palm | Cell proliferation inhibition | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 555 μM |
| dbacp06418 | U7 | NCSIHGDIPAY | Date palm | Cell proliferation inhibition | MTT/MTS assay | T47D | Breast cancer | IC50 : 485.3–702.8 μM |
| dbacp06419 | U7 | NCSIHGDIPAY | Date palm | Cell proliferation inhibition | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 554 μM |
| dbacp06516 | Viscotoxin 1-PS | KSCCPNTTGRNIYNTCRFGGGSREVCARISGCKIISASTCPSDYPK | European mistletoe | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp06518 | Viscotoxin A1 | KSCCPNTTGRNIYNTCRLTGSSRETCAKLSGCKIISASTCPSNYPK | European mistletoe | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp06522 | Viscotoxin A3 | KSCCPNTTGRNIYNACRLTGAPRPTCAKLSGCKIISGSTCPSDYPK | The European mistletoe | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp06523 | Viscotoxin A3 | KSCCPNTTGRNIYNACRLTGAPRPTCAKLSGCKIISGSTCPSDYPK | The European mistletoe | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp06526 | Viscotoxin B2 | KSCCKNTTGRNIYNTCRFAGGSRERCAKLSGCKIISASTCPSDYPK | Korean mistletoe | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp06527 | Viscotoxin B2 | KSCCKNTTGRNIYNTCRFAGGSRERCAKLSGCKIISASTCPSDYPK | Korean mistletoe | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp06529 | Viscotoxin C1 | KSCCPNTTGRNIYNTCRFAGGSRERCAKLSGCKIISASTCPSDYPK | The Asiatic Viscum | Cell membrane disintegration | Not specified | Not found | Breast cancer | Not found |
| dbacp06534 | wtmda-7/IL-24 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL | Not found | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | Cell viability (% of control):0.5 at concentration 7 µg/ml |
| dbacp06536 | wtmda-7/IL-24 | MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL | Not found | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | Apoptotic rate(%) : > 50% at concentration of 8 µg/ml |
| dbacp06543 | XLAsp-P1 | DEDDD | Skin, African clawed frog, Africa | Destruction of the cell membrane | MTT assay | MCF-7 cells | Breast cancer | LC50 : < 5 μg/mL |
| dbacp06549 | Z1 | KAAKKWAKAAKKWAKAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 186 µM |
| dbacp06552 | Z10 | AAKKWAKAKWAKAKKWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : > 211 µM |
| dbacp06555 | Z2 | KAAKKWAKAWKKAAKAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 173 µM |
| dbacp06565 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | Not found |
| dbacp06568 | Z3 | KAAKKAWKAWKKAAKAAWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 128 µM |
| dbacp06571 | Z4 | KAAKKAWKAAKKAAKWWKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 68 µM |
| dbacp06581 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | Not found |
| dbacp06584 | Z5 | KAAKKAWKWAKKAAKWAKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 28 µM |
| dbacp06587 | Z6 | KWWKKAAKAAKKAAKAAKKWA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 16 µM |
| dbacp06590 | Z7 | KAAKKAWKAAKKAWKAAKKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 15 µM |
| dbacp06593 | Z8 | AWKKWAKAWKWAKAKWWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 14 µM |
| dbacp06596 | Z9 | AAWKWAWAKKWAKAKKWAKAA | Synthetic | Disruption of cell membrane | MTT/MTS assay | MT-1 | Breast cancer | EC50 : 16 µM |
| dbacp06614 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Fringed Tree Frog, Australia | Disruption of either cancer or bacterial cell membrane integrity | Not specified | Not specified | Breast cancer | IC50 : 10−5 to 10−6 M |
| dbacp06615 | LA3IK | LAIAVK | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 223.6 ± 5.62 µM |
| dbacp06616 | LA3IK | LAIAVK | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MCF-7 | Breast Cancer | IC50 = 90.23 ± 7.32 µM |
| dbacp06619 | D-LA3IK | laiavk | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 197.72 ± 5.42 µM |
| dbacp06620 | D-LA3IK | laiavk | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MCF-7 | Breast Cancer | IC50 = 91.2 ± 8.21 µM |
| dbacp06623 | LA3IK-SCR | LAKAVI | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 243 ± 8.16 µM |
| dbacp06624 | LA3IK-SCR | LAKAVI | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MCF-7 | Breast Cancer | IC50 = 133 ± 9.52 µM |
| dbacp06627 | RP-7 | RPPCVIL | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 139.03 ± 8.41 µM |
| dbacp06628 | RP-7 | RPPCVIL | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MCF-7 | Breast Cancer | IC50 = 110.12 ± 4.23 µM |
| dbacp06631 | D-RP-7 | rppcvil | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 95 ± 7.71 µM |
| dbacp06632 | D-RP-7 | rppcvil | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MCF-7 | Breast Cancer | IC50 = 90 ± 10.31 µM |
| dbacp06635 | RP7 SCR | RPPLVIC | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 156 ± 8.15 µM |
| dbacp06636 | RP7 SCR | RPPLVIC | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | MCF-7 | Breast Cancer | IC50 = 150 ± 10.32 µM |
| dbacp06641 | C-Mel | CGIGAVLKVLTTGLPALISWIKRKRQQ | Synthetic analogue | Plasma memberane pore formation | MTT assay | MCF-7 | Breast Cancer | IC50 = 110.59 µg/mL |
| dbacp06644 | CM–FA | CGIGAVLKVLTTGLPALISWIKRKRQQ | Synthetic analogue | Plasma memberane pore formation | MTT assay | MCF-7 | Breast Cancer | IC50 = 10.38 µg/mL |
| dbacp06647 | Mel-C | GIGAVLKVLTTGLPALISWIKRKRQQC | Synthetic analogue | Plasma memberane pore formation | MTT assay | MCF-7 | Breast Cancer | IC50 = 160.62 µg/mL |
| dbacp06650 | MC–FA | GIGAVLKVLTTGLPALISWIKRKRQQC | Synthetic analogue | Plasma memberane pore formation | MTT assay | MCF-7 | Breast Cancer | IC50 = 12.63 µg/mL |
| dbacp06673 | Crabrolin | FLPLILRKIVTAL | European hornet (Vespa crabro) | Not available | MTT assay | MCF-7 | Breast Cancer | IC50 = 26.49 μM |
| dbacp06678 | Crabrolin-4R | FLPRILRKIVTAL | Synthetic Analog of Crabrolin | Not available | MTT assay | MCF-7 | Breast Cancer | IC50 = 20.26 μM |
| dbacp06683 | Crabrolin-4K | FLPKILRKIVTAL | Synthetic Analog of Crabrolin | Not available | MTT assay | MCF-7 | Breast Cancer | IC50 = 23.18 μM |
| dbacp06688 | Crabrolin-TR | FLPRILRKIVRAL | Synthetic Analog of Crabrolin | Not available | MTT assay | MCF-7 | Breast Cancer | IC50 = 3.459 μM |
| dbacp06693 | Crabrolin-FR | RLPRILRKIVRAL | Synthetic Analog of Crabrolin | Not available | MTT assay | MCF-7 | Breast Cancer | IC50 = 33.85 μM |
| dbacp06698 | Crabrolin-AR | RLPRILRKIVRRL | Synthetic Analog of Crabrolin | Not available | MTT assay | MCF-7 | Breast Cancer | IC50 = 32.51 μM |
| dbacp06703 | Crabrolin-PR | RLRRILRKIVRRL | Synthetic Analog of Crabrolin | Not available | MTT assay | MCF-7 | Breast Cancer | IC50 = 12.29 μM |
| dbacp06722 | GE18 | GAGIVVASIDTGVRVSHE | Aphanomyces invadans | Not available | MTT assay | MCF-7 | Breast Cancer | IC50 = 35.34 µM |
| dbacp06743 | M1-20 | grrrqrrkkrlgpfsidllikslsdnmtdl | Synthetic | Inhibits FOXM1 transcriptional activities | CCK-8 assay | MDA-MB-231 | Breast Cancer | IC50 = 18.15 µM |
| dbacp06744 | M1-20 | grrrqrrkkrlgpfsidllikslsdnmtdl | Synthetic | Inhibits FOXM1 transcriptional activities | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 31.05 µM |
| dbacp06745 | M1-20 | grrrqrrkkrlgpfsidllikslsdnmtdl | Synthetic | Inhibits FOXM1 transcriptional activities | CCK-8 assay | ZR-75-30 | Breast Cancer | IC50 = 23.57 µM |
| dbacp06757 | ATMP5 | THPPTTTTTTTTTTTYTAAPATTT | Synthetic Analog of ATMP1 | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 64.04 ± 0.021 μg /ml |
| dbacp06758 | ATMP1 | THPPTTTTTTTTTTTYTAAPATTT | Anabas testudineus | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 8.25 ± 0.14 μg/ml |
| dbacp06761 | RP7 | ATRQPNH | RAGE(receptor for advanced glycation end product) inhibitor | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 24.5 µM |
| dbacp06762 | RP7 | ATRQPNH | RAGE(receptor for advanced glycation end product) inhibitor | Apoptosis inducing | MTT assay | BT-549 | Breast Cancer | IC50 = 29.9 µM |
| dbacp06763 | M1-21 | rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF | Synthetic | FOXM1 inhibitor | Cell Viability assay | MDA-MB-231 | Breast Cancer | IC50 = 24.25 µM |
| dbacp06770 | M1-21 | rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF | Synthetic | FOXM1 inhibitor | Cell Viability assay | ZR-75-30 | Breast Cancer | IC50 = 12.92 µM |
| dbacp06771 | Moricin | AKIPIKAAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKA | Bombyx mori | Peptide-induced cell death | MTT assay | MDA-MB-231 | Triple-negative Breast Cancer | 70% cell viability at 6.25 µg/ml |
| dbacp06772 | Moricin | AKIPIKAAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKA | Bombyx mori | Peptide-induced cell death | LDH release assay | MDA-MB-231 | Triple-negative Breast Cancer | Significant decrease in cell viability at 6.25 μg/ml |
| dbacp06773 | Moricin | AKIPIKAAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKA | Bombyx mori | Peptide-induced cell death | Trypan blue assay | MDA-MB-231 | Triple-negative Breast Cancer | 70% cell viability at 6.25 µg/ml |
| dbacp06774 | PMAP-NC | RIIDRLWLVRRPQKPKFVLVWVL | Synthetic Analgog of PMAP-23 | Membrane permeabilization | MTT assay | MDA-MB-361 | Breast Cancer | IC50 = 6.4 μM |
| dbacp06791 | PS9 | PSRKVMLWS | Aphanomyces invadans | Reactive Oxygen Species and Apoptotic Pathways | Neutral Red Uptake assay | MCF-7 | Breast Cancer | IC50 value range between 25.27 - 43.28 μM |
| dbacp06792 | PS9 | PSRKVMLWS | Aphanomyces invadans | Reactive Oxygen Species and Apoptotic Pathways | LDH leakage assay | MCF-7 | Breast Cancer | 71.25 ± 1.3% LDH release at 40 μM |
| dbacp06796 | LHRH-BinBC | QHWSYGLRPGGRGPKDAVRAVKGSALLPCIIVHDPNLNNSDKMKFNTYYLLEYKEYWHQLWSQIIPAHQTVKIQERTGISEVVQNSMIEDLNMYIGADFGMYFYLRSSGFKEQITRGLNRPLSQTTTQLGERVEEMEYYNSNDLDVRYVKYALAREFTLKRVNGEIVKNWVAVDYRMAGIQSYPNAPITNPLTLT | Synthetic | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 10.96 μM |
| dbacp06797 | LHRH-BinBC | QHWSYGLRPGGRGPKDAVRAVKGSALLPCIIVHDPNLNNSDKMKFNTYYLLEYKEYWHQLWSQIIPAHQTVKIQERTGISEVVQNSMIEDLNMYIGADFGMYFYLRSSGFKEQITRGLNRPLSQTTTQLGERVEEMEYYNSNDLDVRYVKYALAREFTLKRVNGEIVKNWVAVDYRMAGIQSYPNAPITNPLTLT | Synthetic | Apoptosis inducing | LDH leakage assay | MCF-7 | Breast Cancer | 40% LDH efflux at 16 µM |
| dbacp06800 | A11 | EYVQTVKSSKG | Annexin A1 | Targeting PD-L1 | Biotin Pull Down assay | MDA-MB-231 | Breast Cancer | Not Available |
| dbacp06806 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MCF-7 | Breast Cancer | CC50 = 29.0 ± 3.7 μM |
| dbacp06812 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MCF-7 | Breast Cancer | CC50 = 15.2 ± 1.9 μM |
| dbacp06822 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MCF-7 | Breast Cancer | CC50 = 37.5 ± 3.3 μM |
| dbacp06828 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MCF-7 | Breast Cancer | CC50 = 6.7 ± 0.7 μM |
| dbacp06834 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MCF-7 | Breast Cancer | CC50 = 48.4 ± 0.7 μM |
| dbacp06840 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MCF-7 | Breast Cancer | CC50 = 15.1 ± 1.4 μM |
| dbacp06842 | Api8-NH2 | UGLUGGLZGI | Trichogin GA | Not available | MTS assay | MDA-MB-231 | Breast Cancer | IC50 > 20 µM |
| dbacp06843 | Leu4-NH2 | UGLLGGLUGI | Trichogin GA | Not available | MTS assay | MDA-MB-231 | Breast Cancer | IC50 > 20 µM |
| dbacp06844 | K2569-Lol | UKLUKKLUKI | Trichogin GA | Not available | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 12 µM |
| dbacp06845 | K259-NH2 | UKLUKGLUKI | Trichogin GA | Not available | MTS assay | MDA-MB-231 | Breast Cancer | IC50 =13 µM |
| dbacp06846 | K259-Lol | UKLUKGLUKI | Trichogin GA | Not available | MTS assay | MDA-MB-231 | Breast Cancer | IC50 =10 µM |
| dbacp06847 | K25-Lol | UKLUKGLUGI | Trichogin GA | Not available | MTS assay | MDA-MB-231 | Breast Cancer | IC50 =9 µM |
| dbacp06848 | K56-Lol | UGLUKKLUGI | Trichogin GA | Not available | MTS assay | MDA-MB-231 | Breast Cancer | IC50 =12 µM |
| dbacp06849 | K6-NH2 | UGLUGKLUGI | Trichogin GA | Not available | MTS assay | MDA-MB-231 | Breast Cancer | IC50 =8 µM |
| dbacp06850 | K2-NH2 | UKLUGGLUGI | Trichogin GA | Not available | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 9 µM |
| dbacp06868 | LfcinB(21-25)Pal | RWQWRWQWR | LfcinB | Apoptosis inducing | MTT assay | MDA-MB-468 | Breast Cancer | IC50 = 72 µM |
| dbacp06869 | LfcinB(21-25)Pal | RWQWRWQWR | LfcinB | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 103 µM |
| dbacp06870 | LfcinB(21-25)Pal | RWQWRWQWR | LfcinB | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 81 µM |
| dbacp06871 | RR-1-RR | RRWQWRWQWRR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 58 µM |
| dbacp06872 | RR-1-RR | RRWQWRWQWRR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 67 µM |
| dbacp06873 | R-1-RR | RWQWRWQWRR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 122 µM |
| dbacp06874 | R-1-RR | RWQWRWQWRR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 95 µM |
| dbacp06875 | RR-1-R | RRWQWRWQWR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 68 µM |
| dbacp06876 | RR-1-R | RRWQWRWQWR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 73 µM |
| dbacp06877 | 1 | WQWRWQW | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 105 µM |
| dbacp06878 | 1 | WQWRWQW | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 > 170 µM |
| dbacp06879 | R-1 | RWQWRWQW | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 58 µM |
| dbacp06880 | R-1 | RWQWRWQW | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 > 150 µM |
| dbacp06881 | 1-R | WQWRWQWR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 130 µM |
| dbacp06882 | 1-R | WQWRWQWR | Synthetic analogue of LfcinB(21-25)Pal | Apoptosis inducing | MTT assay | MDA-MB-231 | Breast Cancer | IC50 > 150 µM |
| dbacp06910 | mtp1 | DGDWDAWTRETS | Synthetic | Disrupts transcription | MTS assay | MDA-MB-231 | Breast Cancer | 33.6% decrease in cell viability at 10 μM |
| dbacp06922 | Ocellatin-3N | GIFDVLKNLAKGVITSLAS | Leptodactylus nesiotus | Not available | CellTiter-Glo assay | MDA-MB-231 | Breast Cancer | LC50 = 51 ± 16 μM |
| dbacp06925 | #2(D33-N52) | RRRRRRRRGGDRDYKKFWAGLQGLTIYFYN | STAP-2 PH domain–derived peptide | Inhibition of cell signalling | CellTiter-Glo assay | MCF-7 | Breast Cancer | Graph figure 1-B |
| dbacp06928 | #6(M108-L127) | RRRRRRRRGGMWKGFILTVVELRVPTDLTL | STAP-2 PH domain–derived peptide | Inhibition of cell signalling | CellTiter-Glo assay | MCF-7 | Breast Cancer | Graph figure 1-B |
| dbacp06978 | C16-E4Y | EEEEY | Synthetic | Inhibition of cell signalling | WST-8 assay | MCF-7 | Breast Cancer | 50 % cell viability at 0.05 wt % |
| dbacp07007 | ST101 | vaeareelerlearlgqargelkkwkmrrnqfwlklqr | Synthetic | Prevents C/EBPβ dimerization, induces degradation | Annexin V/ PI staining assay | MCF-7 | Breast Cancer | mean EC50 value of 2.1 ± 0.4 μmol/L |
| dbacp07015 | NAF-1 | FLGVLALLGYLAVRPFLPKKKQQK | NAF-1/CISD2 | Mitochondria-ER targeting, induces multimodal death. | Not Available | MDA-MB-231 | Breast Cancer | IC50 = 18.3 ± 0.4 μM |
| dbacp07016 | D-NAF-1 | flgvlallgylavrpflpkkkqqk | NAF-1/CISD2 | Mitochondria-ER targeting, induces multimodal death. | Not Available | MDA-MB-231 | Breast Cancer | IC50 = 12.8 ± 0.2 μM |
| dbacp07023 | [G10a]-SHa | FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | MCF-7 | Breast Cancer | IC50 = 15.05 ± 8.51 µM |
| dbacp07030 | [G10a]2-SHa | FLSGIVGMLaKLFKFLKaLMFLSGIVG | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | MCF-7 | Breast Cancer | IC50 = 5.69 ± 1.46 µM |
| dbacp07037 | [G10a]3-SHa | FLSGIVGMLaKLFFLSGIVGMLaKLFFLSGIVGMLaKLFKK | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | MCF-7 | Breast Cancer | IC50 = 3.77 ± 0.12 µM |
| dbacp07044 | Jeff-[G10a]2-SHa | FLSGIVGMLaKLF-jeff-FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | MCF-7 | Breast Cancer | IC50 = 35.71 ± 8.50 µM |
| dbacp07088 | HB43 | FAKLLAKLAKKLL | Synthetic | Motif-driven membrane insertion triggers cytotoxicity | AlamarBlue assay | MDA-MB-231 | Breast Cancer | 50% cell viability at 20 μM |
| dbacp07092 | HB43-mut2 | FAKLLAKLAKLLK | Synthetic | Motif-driven membrane insertion triggers cytotoxicity | AlamarBlue assay | MDA-MB-231 | Breast Cancer | 80% cell viability at 20 μM |
| dbacp07096 | HB43-mut3 | FAKLLAKLARRLL | Synthetic | Motif-driven membrane insertion triggers cytotoxicity | AlamarBlue assay | MDA-MB-231 | Breast Cancer | 75% cell viability at 20 μM |
| dbacp07110 | Nigrocin-M1 | GLLGKILGAGKKVLLGVSGLL | Synthetic | Membrane disruption mediates selective cytotoxicity. | MTT assay | MCF-7 | Breast Cancer | IC50 = 24.60 μM |
| dbacp07111 | LyeTx-I-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Synergistic autophagic death via AKT inhibition. | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 2.47 µM |
| dbacp07113 | Galaxamide | (N-Me-L)L(N-Me-L)LL | Galaxaura filamentosa | Cell-cycle arrest induces apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 11.33 ± 2.95 µg/ml |
| dbacp07115 | Galaxamide | (N-Me-L)L(N-Me-L)LL | Galaxaura filamentosa | Cell-cycle arrest induces apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 8.73 ± 0.29 µg/ml |
| dbacp07117 | Z-1 | L(N-Me-L)LPL | Synthetic | Cell-cycle arrest induces apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 5.85 ± 1.28 µg/ml |
| dbacp07119 | Z-1 | L(N-Me-L)LPL | Synthetic | Cell-cycle arrest induces apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 17.81 ± 0.6 µg/ml |
| dbacp07122 | DEE | GLLDLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 5.55 ± 0.35 µM |
| dbacp07123 | DEE | GLLDLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 6.05 ± 2.76 µM |
| dbacp07125 | EEE | GLLELLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 6.25 ± 1.77 µM |
| dbacp07126 | EEE | GLLELLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 10.55 ± 3.46 µM |
| dbacp07128 | HEE | GLLHLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 6.50 ± 0.71 µM |
| dbacp07129 | HEE | GLLHLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 4.95 ± 0.49 µM |
| dbacp07131 | KEE | GLLKLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.75 ± 0.78 µM |
| dbacp07132 | KEE | GLLKLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.05 ± 0.21 µM |
| dbacp07134 | DHE | GLLDLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.75 ± 0.92 µM |
| dbacp07135 | DHE | GLLDLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.80 ± 0.14 µM |
| dbacp07137 | EHE | GLLELLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.90 ± 0.28 µM |
| dbacp07138 | EHE | GLLELLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.55 ± 0.07 µM |
| dbacp07140 | HHE | GLLHLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 16.70 ± 2.26 µM |
| dbacp07141 | HHE | GLLHLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 10.75 ± 0.78 µM |
| dbacp07143 | KHE | GLLKLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.70 ± 0.14 µM |
| dbacp07144 | KHE | GLLKLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.92 ± 0.17 µM |
| dbacp07146 | DKE | GLLDLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.10 ± 0 µM |
| dbacp07147 | DKE | GLLDLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.57 ± 0.33 µM |
| dbacp07149 | EKE | GLLELLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.80 ± 0.28 µM |
| dbacp07150 | EKE | GLLELLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.30 ± 0.14 µM |
| dbacp07152 | HKE | GLLHLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.70 ± 0.28 µM |
| dbacp07153 | HKE | GLLHLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.90 ± 0.42 µM |
| dbacp07155 | KKE | GLLKLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.05 ± 0.64 µM |
| dbacp07156 | KKE | GLLKLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.70 ± 0 µM |
| dbacp07158 | DEH | GLLDLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 5.35 ± 1.91 µM |
| dbacp07159 | DEH | GLLDLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 3.60 ± 0.42 µM |
| dbacp07161 | EEH | GLLELLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.30 ± 0.14 µM |
| dbacp07162 | EEH | GLLELLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 3.60 ± 0.85 µM |
| dbacp07164 | HEH | GLLHLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 28.60 ± 10.75 µM |
| dbacp07165 | HEH | GLLHLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 10.95 ± 1.06 µM |
| dbacp07167 | KEH | GLLKLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.30 ± 0.42 µM |
| dbacp07168 | KEH | GLLKLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.35 ± 0.07 µM |
| dbacp07170 | DHH | GLLDLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 21.45 ± 2.47 µM |
| dbacp07171 | DHH | GLLDLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 11.90 ± 0.14 µM |
| dbacp07173 | EHH | GLLELLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 25.35 ± 2.76 µM |
| dbacp07174 | EHH | GLLELLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 16.05 ± 3.18 µM |
| dbacp07176 | HHH | GLLHLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 21.10 ± 6.93 µM |
| dbacp07177 | HHH | GLLHLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 9.50 ± 0.99 µM |
| dbacp07179 | KHH | GLLKLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 5.20 ± 0.71 µM |
| dbacp07180 | KHH | GLLKLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 4.45 ± 0.49 µM |
| dbacp07182 | DKH | GLLDLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.45 ± 0.07 µM |
| dbacp07183 | DKH | GLLDLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.80 ± 0.28 µM |
| dbacp07185 | EKH | GLLELLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.75 ± 0.07 µM |
| dbacp07186 | EKH | GLLELLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.18 ± 0.31 µM |
| dbacp07188 | HKH | GLLHLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.45 ± 0.21 µM |
| dbacp07189 | HKH | GLLHLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 3.10 ± 0.57 µM |
| dbacp07191 | KKH | GLLKLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.40 ± 0.85 µM |
| dbacp07192 | KKH | GLLKLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.20 ± 0.42 µM |
| dbacp07194 | DEK | GLLDLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.14 ± 0.52 µM |
| dbacp07195 | DEK | GLLDLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 0.70 ± 0.07 µM |
| dbacp07197 | EEK | GLLELLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.10 ± 0.14 µM |
| dbacp07198 | EEK | GLLELLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.08 ± 0.18 µM |
| dbacp07200 | HEK | GLLHLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.35 ± 1.06 µM |
| dbacp07201 | HEK | GLLHLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 3.45 ± 2.19 µM |
| dbacp07203 | KEK | GLLKLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.60 ± 0.14 µM |
| dbacp07204 | KEK | GLLKLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.35 ± 0.07 µM |
| dbacp07206 | DHK | GLLDLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.75 ±0.49 µM |
| dbacp07207 | DHK | GLLDLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.02 ± 0.12 µM |
| dbacp07209 | EHK | GLLELLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.35 ± 0.35 µM |
| dbacp07210 | EHK | GLLELLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 0.71 ± 0.13 µM |
| dbacp07212 | HHK | GLLHLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.15 ± 0.07 µM |
| dbacp07213 | HHK | GLLHLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.75 ± 0.21 µM |
| dbacp07215 | KHK | GLLKLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.59 ± 0.92 µM |
| dbacp07216 | KHK | GLLKLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.40 ± 0.14 µM |
| dbacp07218 | DKK | GLLDLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.95 ± 0.35 µM |
| dbacp07219 | DKK | GLLDLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.20 ± 0.14 µM |
| dbacp07221 | EKK | GLLELLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.72 ± 0.21 µM |
| dbacp07222 | EKK | GLLELLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.19 ± 0.40 µM |
| dbacp07224 | HKK | GLLHLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.40 ± 0.71 µM |
| dbacp07225 | HKK | GLLHLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.60 ± 0.42 µM |
| dbacp07227 | KKK | GLLKLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.57 ± 0.24 µM |
| dbacp07228 | KKK | GLLKLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.35 ± 0.40 µM |
| dbacp07230 | d-DHK | GlldllhlllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 0.32 ± 0.07 µM |
| dbacp07231 | d-DHK | GlldllhlllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 0.23 ± 0.04 µM |
| dbacp07233 | d-DEK | GlldllelllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 0.44 ± 0.10 µM |
| dbacp07234 | d-DEK | GlldllelllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 0.36 ± 0 µM |
| dbacp07236 | d-EEK | GllellelllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 0.29 ± 0.01 µM |
| dbacp07237 | d-EEK | GllellelllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 0.29 ± 0.01 µM |
| dbacp07243 | RB4 | MADSERLSAPGCWAACTNFSRTRK | Derived from protein PLP2 | F-actin modulation induces necrotic death. | MTT assay | MCF-7 | Breast Cancer | EC50 = 0.724 ± 0.340 mol/L × 10-3 |
| dbacp07283 | AtMP1 | THPPTTTTTTTTTTTTTAAPATTT | Anabastestudineus skin mucus fraction 2 | p53-mediated Bax/Bcl-2 apoptosis activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 8.25 ± 0.14 μg/ml |
| dbacp07284 | AtMP1 | THPPTTTTTTTTTTTTTAAPATTT | Anabastestudineus skin mucus fraction 2 | p53-mediated Bax/Bcl-2 apoptosis activation | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 9.35 ± 0.25 μg/ml |
| dbacp07285 | AtMP2 | TGIATSGLATFTLHTGSLAPAT | Anabastestudineus skin mucus fraction 2 | p53-mediated Bax/Bcl-2 apoptosis activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 5.89 ± 0.14 μg/ml |
| dbacp07286 | AtMP2 | TGIATSGLATFTLHTGSLAPAT | Anabastestudineus skin mucus fraction 2 | p53-mediated Bax/Bcl-2 apoptosis activation | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 6.97 ± 0.24 μg/ml |
| dbacp07296 | vCPP0275 | KKRYKKKYKAYKPYKKKKKF | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | BT-20 | Breast Cancer | IC50 = 44.8 ± 1.1 μM |
| dbacp07297 | vCPP0275 | KKRYKKKYKAYKPYKKKKKF | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | SK-BR-3 | Breast Cancer | IC50 = 34.0 ± 1.0 μM |
| dbacp07298 | vCPP0667 | RPRRRATTRRRITTGTRRRR | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | BT-20 | Breast Cancer | IC50 = 88.8 ± 1.0 μM |
| dbacp07299 | vCPP0667 | RPRRRATTRRRITTGTRRRR | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | BT-474 | Breast Cancer | IC50 = 92.8 ± 1.1 μM |
| dbacp07300 | vCPP0667 | RPRRRATTRRRITTGTRRRR | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | SK-BR-3 | Breast Cancer | IC50 = 71.2 ± 1.1 μM |
| dbacp07301 | vCPP0769 | RRLTLRQLLGLGSRRRRRSR | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 9.0 ± 0.1 μM |
| dbacp07302 | vCPP0769 | RRLTLRQLLGLGSRRRRRSR | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | BT-20 | Breast Cancer | IC50 = 3.5 ± 1.5 μM |
| dbacp07303 | vCPP0769 | RRLTLRQLLGLGSRRRRRSR | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | BT-474 | Breast Cancer | IC50 = 37.5 ± 1.7 μM |
| dbacp07304 | vCPP0769 | RRLTLRQLLGLGSRRRRRSR | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | SK-BR-3 | Breast Cancer | IC50 = 21.1 ± 2.0 μM |
| dbacp07305 | vCPP2319 | WRRRYRRWRRRRRWRRRPRR | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 4.5 ± 0.1 μM |
| dbacp07306 | vCPP2319 | WRRRYRRWRRRRRWRRRPRR | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | BT-20 | Breast Cancer | IC50 = 4.2 ± 2.2 μM |
| dbacp07307 | vCPP2319 | WRRRYRRWRRRRRWRRRPRR | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | BT-474 | Breast Cancer | IC50 = 15.7 ± 1.5 μM |
| dbacp07308 | vCPP2319 | WRRRYRRWRRRRRWRRRPRR | Capsid protein of the Torque teno douroucouli virus | Dual anticancer and BBB-blockade. | MTT assay | SK-BR-3 | Breast Cancer | IC50 = 14.0 ± 1.0 μM |
| dbacp07309 | LyeTxI-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Apoptosis induction and immune modulation. | MTT assay | 4T1 | Breast Cancer | IC50 = 6.5 ± 5.30 µM |
| dbacp07310 | LyeTxI-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Apoptosis induction and immune modulation. | MTT assay | MCF-7 | Breast Cancer | IC50 = 7.34 ± 3.09 µM |
| dbacp07311 | LyeTxI-b | IWLTALKFLGKNLGKLAKQQLAKL | Synthetic | Apoptosis induction and immune modulation. | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 5.77 ± 0.83 µM |
| dbacp07315 | B1OS-L | FLPLIASLAGNVVPKIFCKITKRC | B-1OS | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 = 8.883 µM |
| dbacp07320 | B1OS-D-L | FlPLIASLAGNVVPKIFCKITKRC | B-1OS | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 = 3.17 µM |
| dbacp07341 | D-melittin | gigavlkvlttglpaliswikrkrqqc | Synthetic | pH-triggered release, membrane lysis, immunogenic death | MTS assay | MDA-MB-435 WT | Breast Cancer | IC50 = 3.5 µM |
| dbacp07342 | D-melittin | gigavlkvlttglpaliswikrkrqqc | Synthetic | pH-triggered release, membrane lysis, immunogenic death | MTS assay | MDA-MB-435 DOX-R | Breast Cancer | IC50 = 3.4 µM |
| dbacp07347 | GA - 2 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 7.70 ± 1.3 µg/mL |
| dbacp07349 | GA - 3 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 5.1 ± 0.7 µg/mL |
| dbacp07351 | GA - 4 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 6.10 ± 0.4 µg/mL |
| dbacp07353 | GA - 5 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 5.0 ± 0.3 µg/mL |
| dbacp07355 | GA - 7 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 3.70 ± 0.2 µg/mL |
| dbacp07358 | GA - 8 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 6.90 ± 1.1 µg/mL |
| dbacp07363 | Pal-N-Ter-TAT | Pal-RDVFTKGYGFGL-GRK(Dansylglycine)KRRQRRRPQ | Analogue of N-terminal fragment of the VDAC1 protein | Mitochondrial targeting, VDAC1-HKII dissociation | MTT assay | MCF-7 | Breast Cancer | IC50 = 27.26 μM |
| dbacp07367 | Piscidin 3 | FIHHIFRGIVHAGRSIGRFLTG | Morone chrysops x Morone saxatilis | Cu²⁺-mediated membrane lipid oxidation | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 17.5 µM |
| dbacp07368 | Piscidin 3 | FIHHIFRGIVHAGRSIGRFLTG | Morone chrysops x Morone saxatilis | Cu²⁺-mediated membrane lipid oxidation | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 5.25 µM |
| dbacp07376 | Brevinin-2DYd | GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC | Rana dybowskii | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 = 25.74 µg/ml |
| dbacp07380 | Ranatuerin-2Lb | GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC | Rana luteiventris | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 = 45.25 µM |
| dbacp07384 | Odorranain-C1 | GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC | Odorrana grahami | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 = 41.21 µM |
| dbacp07388 | Brevinin-2DYb | GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC | Rana dybowskii | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 = 37.84 µM |
| dbacp07392 | Ranatuerin-2 | GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP | Rana catesbeiana | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 > 128 µM |
| dbacp07397 | Pugnin A | RLMRIFRILKLAR | Synthetic | Membrane disruption induces necrotic death | MTT assay | MCF-7 | Breast Cancer | 12% Cytotoxicity at 100 µM |
| dbacp07399 | Pugnin B | RMMRIFWVIKLAR | Synthetic | Membrane disruption induces necrotic death | MTT assay | MCF-7 | Breast Cancer | 5% Cytotoxicity at 100 µM |
| dbacp07403 | Pep | GKLRLIKKLWVKKWKKKGWKA | Synthetic | Membrane disruption induces necrotic death | MTT assay | MCF-7 | Breast Cancer | IC50 = 2 µM |
| dbacp07411 | Si1 | (KLAKLAK)2 | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 124.1 ± 8.12 µM |
| dbacp07412 | Si1 | (KLAKLAK)2 | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 746.5 ± 7.6 µM |
| dbacp07413 | Si3 | KL(Beta-A)KL(Beta-A)AK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 176.3 ± 4.66 µM |
| dbacp07414 | Si2 | KL(Beta-A)KL(Beta-A)K | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 662.9 ± 20.02 µM |
| dbacp07415 | Si2 | KL(Beta-A)KL(Beta-A)K | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 840 ± 21.18 µM |
| dbacp07416 | Si11 | KL(Beta-A)KL(Beta-A)K | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 1087 ± 70.71 µM |
| dbacp07417 | Si11 | KL(Beta-A)KLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 228.8 ± 7.18 µM |
| dbacp07418 | Si13 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 1704 ± 112 µM |
| dbacp07419 | Si14 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 593.3 ± 60.3 µM |
| dbacp07420 | Si14 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 1049 ± 49.77 µM |
| dbacp07421 | Si15 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 140.3 ± 7.12 µM |
| dbacp07422 | Si15 | KnLAKnLAK | Synthetic | Membrane disruption induces cancer apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 346.3 ± 7.91 µM |
| dbacp07432 | [Arg]3-VmCT1 | FLRALWNVAKSVF | Synthetic | Membrane disruption via cationic interaction | MTT assay | MCF-7 | Breast Cancer | IC50 = 20.6 ± 3.1 μmol/L |
| dbacp07433 | [Arg]7-VmCT1 | FLGALWRVAKSVF | Synthetic | Membrane disruption via cationic interaction | MTT assay | MCF-7 | Breast Cancer | IC50 = 18.0 ± 2.7 μmol/L |
| dbacp07434 | [Arg]11-VmCT1 | FLGALWNVAKRVF | Synthetic | Membrane disruption via cationic interaction | MTT assay | MCF-7 | Breast Cancer | IC50 = 25.8 ± 5.2 μmol/L |
| dbacp07440 | A4K14 - Citropin 1.1 - Sp 7 | GLFAVR8KKVASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 12.1 µM |
| dbacp07444 | A4K14 - Citropin 1.1 - Sp 6 | GR8FAVIKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 23.78 µM |
| dbacp07448 | A4K14 - Citropin 1.1 - Sp 5 | GLFAVIKKVAS5VIKS5L | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 12.42 µM |
| dbacp07452 | A4K14 - Citropin 1.1 - Sp 4 | GLFAVIKKS5ASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 10.49 µM |
| dbacp07456 | A4K14 - Citropin 1.1 - Sp 3 | GLFAVS5KKVS5SVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 11.92 µM |
| dbacp07460 | A4K14 - Citropin 1.1 - Sp 2 | GLFAS5IKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 12.65 µM |
| dbacp07464 | A4K14 - Citropin 1.1 - Sp 1 | GS5FAVS5KKVASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 11.26 µM |
| dbacp07473 | MzDef | MSSSNCANVCQTENFPGGECKAEGATRKCFCKNC | Zea mays L. | Disulfide-stabilized peptide disrupts pathogens | MTT assay | MCF-7 | Breast Cancer | IC50 = 14.85 µg/mL |
| dbacp07475 | Latcripin-7A | MTTESKVKNATTLLHSGKVKERQEGLSALRNIFSQNSSIERFYNVAGRDGRKPSHEIWAPILDGLQTCIRSEKSAFVTAKKSTDVIEKRLAAAAGTYRWFVEKSMMHFAKKTVLEICHFLYREMKVRETLIPSVALDFIKAYECVASHPPHLARLEEDEIEWEE | Lentinula edodes | Cell-cycle arrest, apoptosis, autophagy induction | CCK-8 assay | MCF-7 | Breast Cancer | IC50 = 91 μg/mL |
| dbacp07476 | Latcripin-7A | MTTESKVKNATTLLHSGKVKERQEGLSALRNIFSQNSSIERFYNVAGRDGRKPSHEIWAPILDGLQTCIRSEKSAFVTAKKSTDVIEKRLAAAAGTYRWFVEKSMMHFAKKTVLEICHFLYREMKVRETLIPSVALDFIKAYECVASHPPHLARLEEDEIEWEE | Lentinula edodes | Cell-cycle arrest, apoptosis, autophagy induction | CCK-8 assay | MDA-MB-231 | Breast Cancer | IC50 = 122 μg/mL |
| dbacp07479 | (LLKK)4 linear peptide | LLKKLLKKLLKKLLKK | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | Bcap-37 | Breast Cancer | Cell Viability (%) ~ 15.07 ± 0.5 at 30 µg/mL |
| dbacp07483 | 2-arm branched peptide | [LLKKLLKK]2kC | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | Bcap-37 | Breast Cancer | Cell Viability (%) ~ 81.8 ± 8.8 at 30 µg/mL |
| dbacp07487 | 4-arm branched peptide | {[LLKKLLKK]2kC}2 | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | Bcap-37 | Breast Cancer | Cell Viability (%) ~ 51.4 ± 4.2 at 30 µg/mL |
| dbacp07489 | LRH7-G5 | Not Available | Synthetic | GPR1 antagonism, PI3K/AKT inhibition | MTT assay | MDA-MB-231 | Breast Cancer | 60% cell viability at 0.01 μM |
| dbacp07490 | LRH7-G5 | Not Available | Synthetic | GPR1 antagonism, PI3K/AKT inhibition | MTT assay | HCC-1937 | Breast Cancer | 60% cell viability at 0.1 μM |
| dbacp07491 | Figainin 1 | FIGTLIPLALGALTKLFK | Boana raniceps | Membrane disruption, α-helix mediated | MTT assay | MCF-7 | Breast Cancer | IC50 = 13.7 µM |
| dbacp07495 | RA-3 | RWrGGGGGLFDIIKKIAESF | Synthetic | Integrin-targeting, α-helix mediated lysis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 28.4 μM |
| dbacp07496 | RA-3 | RWrGGGGGLFDIIKKIAESF | Synthetic | Integrin-targeting, α-helix mediated lysis | MTT assay | MCF-7 | Breast Cancer | IC50 = 44.14 μM |
| dbacp07500 | Mambalgin-1 | LKCYQHGKVVTCHRDMKFCYHNTGMPFRNLKLILQGCSSSCSETENNKCCSTDRCNK | Dendroaspis polylepsis | ASIC inhibition suppresses cancer proliferation | MTT assay | MCF-7 | Breast Cancer | 22.43% cytotoxicity at 10 µg/mL |
| dbacp07502 | Brevinin-1Ha | FALGAVTCLIRTKCKVLPKLF | Analogue of Brevinin-1H | α-helix enhances antimicrobial, anticancer activity | MTT assay | MDA-MB-435S | Breast Cancer | IC50 = 214.7 µM |
| dbacp07506 | Brevinin-1HY | FALGAVTKVLYKLFCLITRKC | Analogue of Brevinin-1H | α-helix enhances antimicrobial, anticancer activity | MTT assay | MDA-MB-435S | Breast Cancer | IC50 = 2.243 µM |
| dbacp07510 | cyclic dipeptide - 2b | WA | Synthetic | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 = 45.6 µM |
| dbacp07513 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 2.92 μM |
| dbacp07534 | rCT-II | LKCKKLVPLFSKTCPAGKNLCYKMFMVAAPHVPVKRGCIDVCPKSSLLVKYVCCNTDKCN | Naja naja | Apoptosis via intrinsic (mitochondrial) and extrinsic (death receptor) pathways | MTT assay | MCF-7 | Breast Cancer | IC50 = 3.66 µg/mL |
| dbacp07552 | macrocyclic pyridoheptapeptide derivative 1a | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 15.329 ± 0.672 μM |
| dbacp07554 | macrocyclic pyridoheptapeptide derivative 1b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 10.904 ± 0.534 μM |
| dbacp07556 | macrocyclic pyridoheptapeptide derivative 1c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 34.894 ± 1.273 μM |
| dbacp07559 | macrocyclic pyridoheptapeptide derivative 2b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 20.697 ± 0.974 μM |
| dbacp07561 | macrocyclic pyridoheptapeptide derivative 2c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 24.943 ± 1.082 μM |
| dbacp07563 | macrocyclic pyridoheptapeptide derivative 3a | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 10.316 ± 0.546 μM |
| dbacp07565 | macrocyclic pyridoheptapeptide derivative 3b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 9.911 ± 0.491 μM |
| dbacp07567 | macrocyclic pyridoheptapeptide derivative 3c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 22.864 ± 0.992 μM |
| dbacp07569 | macrocyclic pyridoheptapeptide derivative 4a | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 9.304 ± 0.536 μM |
| dbacp07571 | macrocyclic pyridoheptapeptide derivative 4b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 9.188 ± 0.545 μM |
| dbacp07573 | macrocyclic pyridoheptapeptide derivative 4c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 19.552 ± 1.032 μM |
| dbacp07638 | branched tetrapeptide Schiff bases derivative 4a | Figure given in Scheme 1 | Synthetic | p53 stabilization and LDHA inhibition | MTT assay | MCF-7 | Breast Cancer | IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM |
| dbacp07639 | branched tetrapeptide Schiff bases derivative 4b | Figure given in Scheme 1 | Synthetic | p53 stabilization and LDHA inhibition | MTT assay | MCF-7 | Breast Cancer | IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM |
| dbacp07640 | branched tetrapeptide Schiff bases derivative 4c | Figure given in Scheme 1 | Synthetic | p53 stabilization and LDHA inhibition | MTT assay | MCF-7 | Breast Cancer | IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM |
| dbacp07641 | branched tetrapeptide Schiff bases derivative 5c | Figure given in Scheme 1 | Synthetic | p53 stabilization and LDHA inhibition | MTT assay | MCF-7 | Breast Cancer | IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM |
| dbacp07642 | branched tetrapeptide Schiff bases derivative 5d | Figure given in Scheme 1 | Synthetic | p53 stabilization and LDHA inhibition | MTT assay | MCF-7 | Breast Cancer | IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM |
| dbacp07643 | branched tetrapeptide Schiff bases derivative 5e | Figure given in Scheme 1 | Synthetic | p53 stabilization and LDHA inhibition | MTT assay | MCF-7 | Breast Cancer | IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM |
| dbacp07647 | AP1-Z1 | FLFSLIPHAISGLISAFK | AcrAP1 from the venom of the Arabian scorpion | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 7.222 μM |
| dbacp07650 | AP1-Z5a | FLFKLIPKAIKGLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | Graph Figure 2A |
| dbacp07653 | AP1-Z5b | FLFKLIKHAIKGLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 1.037 μM |
| dbacp07656 | AP1-Z3a | FLFSLIKHAIKGLISAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | Graph Figure 2A |
| dbacp07659 | AP1-Z3b | FLFSLIKHAISKLISAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | Graph Figure 2A |
| dbacp07662 | AP1-Z7 | FLFKLIKKAIKKLIKAFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | Graph Figure 2A |
| dbacp07665 | AP1-Z9 | FLFKLIKKKIKKLIKKFK | Mutant of APR-Z1 | Charge–hydrophobicity balance drives apoptosis | MTT assay | MCF-7 | Breast Cancer | Graph Figure 2A |
| dbacp07682 | Longicalycinin A | FYPFG | Dianthus superbus | Cyclization enhances apoptosis via lysosomes | MTT assay | EAC cell Line | Breast Cancer | CTC50 = 6.17 µM |
| dbacp07808 | cT1 | KWCFRVCYRGICYRRCRG | Synthetic | Not Available | Resazurin dye assay | MCF-7 | Breast Cancer | CC50 = 6.4 ± 0.6 µM |
| dbacp07849 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Phyllomedusa tarsius | Membrane disruption and cationic enhancement | MTT assay | MCF-7 | Breast Cancer | IC50 = 7.44 µM |
| dbacp07854 | K8, 23-DPT9 | GLWSKIKKAAKTAGKAALGFVNKMV | Synthetic | Membrane disruption and cationic enhancement | MTT assay | MCF-7 | Breast Cancer | IC50 = 8.64 µM |
| dbacp07859 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 6.9 μM |
| dbacp07862 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | MDA-MB-453 | Breast Cancer | Not Available |
| dbacp07864 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | 4T1 | Breast Cancer | Not Available |
| dbacp07865 | R-Lycosin I derivative 8a | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | MDA-MB-231 | Breast Cancer | IC50 = 10.1 ± 0.2 µM |
| dbacp07871 | R-Lycosin I derivative 8b | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | MDA-MB-231 | Breast Cancer | IC50 = 6.0 ± 0.2 µM |
| dbacp07887 | ICD-85 | Not Available | Active fractions from Gloydius halys and Hemiscorpius lepturus | Caspase-9 mediated apoptotic death | MTT assay | MCF-7 | Breast Cancer | IC50 = 36.45 ± 0.38 μg/mL |
| dbacp07888 | ICD-85 | Not Available | Active fractions from Gloydius halys and Hemiscorpius lepturus | Caspase-9 mediated apoptotic death | Neutral Red Uptake assay | MCF-7 | Breast Cancer | IC50 = 21.97 ± 0.63 μg/mL |
| dbacp07926 | Phylloseptin-PBa3 | FLSLIPHIVSGVAALANHL | Phyllomedusa burmeisteri | Membrane disruption, apoptosis, selective cytotoxicity | MTT assay | MDA-MB-435S | Breast Cancer | IC50 = 208 µM |
| dbacp07931 | myristoyl-CM4 | GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI | Bombyx mori | Cell penetration, Mitochondrial dysfunction, Apoptosis pathway activation | MTT assay | MCF-7 | Breast cancer | IC50 = 6 μM |
| dbacp07932 | myristoyl-CM4 | GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI | Bombyx mori | Enhanced binding, mitochondrial dysfunction, apoptosis | MTT assay | MDA-MB-231 | Breast cancer | IC50 = 4 μM |
| dbacp07933 | myristoyl-CM4 | GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI | Bombyx mori | Enhanced binding, mitochondrial dysfunction, apoptosis | MTT assay | MX-1 | Breast cancer | IC50 = 3 μM |
| dbacp07937 | Pantinin-1 | GILGKLWEGFKSIV | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 28.5 ± 1.0 µM |
| dbacp07939 | Pantinin-2 | IFGAIWKGISSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 12.5 ± 1.0 µM |
| dbacp07941 | Pantinin-3 | FLSTIWNGIKSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 13.5 ± 2.0 µM |
| dbacp07944 | TC22 | MTVVLLLIVLPLLGGVHSSGIL | Tribolium castaneum | ROS, p53, mitochondrial apoptosis activation | MTT assay | MCF-7 | Breast Cancer | Fig 4a |
| dbacp07955 | S-24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Synthetic Analogue of Ranatuerin-2PLx | R2PLx induces caspase-dependent apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 316.90 µM |
| dbacp07958 | Compound 2a | Structure in scheme 1 | Synthetic | 5c inhibits cancer via kinase blockade | Not Available | MCF-7 | Breast Cancer | IC50 = 31.64 ± 1.30 µM |
| dbacp07960 | Compound 2b | Structure in scheme 1 | Synthetic | 5c inhibits cancer via kinase blockade | Not Available | MCF-7 | Breast Cancer | IC50 = 32.58 ± 1.50 µM |
| dbacp07964 | Compound 3b | Structure in scheme 2 | Synthetic | 5c inhibits cancer via kinase blockade | Not Available | MCF-7 | Breast Cancer | IC50 = 25.33 ± 1.18 µM |
| dbacp07966 | Compound 3c | Structure in scheme 2 | Synthetic | 5c inhibits cancer via kinase blockade | Not Available | MCF-7 | Breast Cancer | IC50 = 29.55 ± 2.06 µM |
| dbacp07969 | Compound 4b | Structure in scheme 2 | Synthetic | 5c inhibits cancer via kinase blockade | Not Available | MCF-7 | Breast Cancer | IC50 = 10.45 ± 1.33 µM |
| dbacp07971 | Compound 4c | Structure in scheme 2 | Synthetic | 5c inhibits cancer via kinase blockade | Not Available | MCF-7 | Breast Cancer | IC50 = 29.15 ± 1.39 µM |
| dbacp07973 | Compound 5a | Structure in scheme 2 | Synthetic | 5c inhibits cancer via kinase blockade | Not Available | MCF-7 | Breast Cancer | IC50 = 12.67 ± 2.40 µM |
| dbacp07975 | Compound 5b | Structure in scheme 2 | Synthetic | 5c inhibits cancer via kinase blockade | Not Available | MCF-7 | Breast Cancer | IC50 = 11.32 ± 1.15 µM |
| dbacp07977 | Compound 5c | Structure in scheme 2 | Synthetic | 5c inhibits cancer via kinase blockade | Not Available | MCF-7 | Breast Cancer | IC50 = 9.41 ± 1.25 µM |
| dbacp07979 | Compound 6a | Structure in scheme 2 | Synthetic | 5c inhibits cancer via kinase blockade | Not Available | MCF-7 | Breast Cancer | IC50 = 11.83 ± 1.62 µM |
| dbacp07981 | Compound 6b | Structure in scheme 2 | Synthetic | 5c inhibits cancer via kinase blockade | Not Available | MCF-7 | Breast Cancer | IC50 = 10.87 ± 1.10 µM |
| dbacp07993 | [G10a]SHa | FLSGIVGMLaKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | MCF-7 | Breast Cancer | IC50 = 16.2 ± 2.2 µM |
| dbacp07996 | [G10a]SHa-BCTP | FLSGIVGMLaKLFLFKQYAELW | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | MCF-7 | Breast Cancer | IC50 = 26.85 ± 1.85 µM |
| dbacp07999 | [G4a]SHa | FLSaIVGMLGKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | MCF-7 | Breast Cancer | IC50 = 17.9 ± 1.1 µM |
| dbacp08002 | [G7a]SHa | FLSGIVaMLGKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | MCF-7 | Breast Cancer | IC50 =22.4 ± 2.2 µM |
| dbacp08005 | [G4,7a]SHa | FLSaIVaMLGKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | MCF-7 | Breast Cancer | IC50 = 29.5 ± 6.03 µM |
| dbacp08008 | [G4,7,10a]SHa | FLSaIVaMLaKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | MCF-7 | Breast Cancer | IC50 = 26.33 ± 5.8 µM |
| dbacp08011 | [G7,10a]SHa | FLSGIVaMLaKLF | Synthetic analogue of Temporin-1SHa | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | MCF-7 | Breast Cancer | IC50 = 21.3 ± 1.13 µM |
| dbacp08048 | R11-NLS-pep8 | RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa | NKp44 derived synthetic peptide | NKp44-pep8 inhibits PCNA function | PrestoBlue assay | MDA-MD-231 | Breast Cancer | ED50 = 5.6 μM |
| dbacp08049 | Temporin-1Ga | SILPTIVSFLSKVF | Synthetic | Temporin-1OLa disrupts bacterial membranes | MTS assay | 4T1 | Breast Cancer | LC50 = 20 μM |
| dbacp08050 | Temporin-CPa | IPPFIKKVLTTVF | Synthetic | Temporin-1OLa disrupts bacterial membranes | MTS assay | 4T1 | Breast Cancer | LC50 = 80 μM |
| dbacp08052 | Poca A | GLPCAESCVFIPCTITAILGCSCRDRVCYD | Pombalia calceolaria | Cyclotides induce cytotoxicity, inhibit migration | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 1.8 μM |
| dbacp08053 | Poca B | GIPCAESCVFIPCVTAILGCSCKDVCYN | Pombalia calceolaria | Cyclotides induce cytotoxicity, inhibit migration | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 2.7 μM |
| dbacp08054 | CyO4 | GIPCGESCVWIPCISSAIGCSCKNKVCYRN | Viola odorata | Cyclotides induce cytotoxicity, inhibit migration | MTS assay | MDA-MB-231 | Breast Cancer | IC50 = 9.8 μM |
| dbacp08063 | E5 | GGRSFFLLRRIQGCRFRNTVDD | Synthetic | E5 inhibits CXCR4–CXCL12 signaling | CCK-8 assay | 4T1 | Breast Cancer | 49% cell viability at 100 μM |
| dbacp08077 | PvD1 | KTCENLADTYKGPCFTTGSCDDHCKNKEHLRSGRCRDDFRCWCTKNC | Phaseolus vulgaris | Disrupts tumor cells | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 0.82 ± 0.14 µM |
| dbacp08081 | Peptide 3a | YD | Synthetic | Inhibit COX-2 enzyme | MTT assay | MCF-7 | Breast Cancer | IC50 = 17.5 ± 0.04 µM |
| dbacp08086 | L-K6 | IKKILSKIKKLLK | Temporin 1CEb analogue | L-K6 binds, internalizes, damages nucleus | MTT assay | MCF-7 | Breast Cancer | IC50 = 31 μM |
| dbacp08090 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 15.7 ± 1.5 μM |
| dbacp08091 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 18.2 ± 1.3 μM |
| dbacp08094 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 30.8 ± 3.4 μM |
| dbacp08095 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 36.1 ± 6.7 μM |
| dbacp08098 | B3 | KKLFKKILKYLKKL | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 25.3 ± 3.2 μM |
| dbacp08099 | B3 | KKLFKKILKYLKKL | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 28.4 ± 3.1 μM |
| dbacp08101 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 27.3 ± 2.4 μM |
| dbacp08102 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 28.2 ± 2.7 μM |
| dbacp08105 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 18.4 ± 1.5 μM |
| dbacp08106 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 20.7 ± 1.6 μM |
| dbacp08109 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7 | Breast Cancer | IC50 = 38.3 ± 2.5 μM |
| dbacp08110 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | MCF-7/ADM | Breast Cancer | IC50 = 30.6 ± 5.7 μM |
| dbacp08112 | FR-15 | FRRFFKWFRRFFKFF | Synthetic | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 3.15 μM |
| dbacp08116 | FR4P | FRRPFKWFRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 6.3 μM |
| dbacp08120 | FR8P | FRRFFKWPRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 6.4 μM |
| dbacp08124 | FR11P | FRRFFKWFRRPFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 7 μM |
| dbacp08128 | FR4,8P | FRRPFKWPRRFFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 15.4 μM |
| dbacp08132 | FR8,11P | FRRFFKWPRRPFKFF | Analogue of FR-15 | Proline-substituted AMP triggers mitochondrial apoptosis | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 27 μM |
| dbacp08136 | Laterosporulin10 (LS10) | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL | Brevibacillus sp. strain SKDU10 | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | 40% cytotoxicity at 5 μM concentration |
| dbacp08137 | Laterosporulin10 (LS10) | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL | Brevibacillus sp. strain SKDU10 | Apoptosis inducing | LDH leakage assay | MCF-7 | Breast Cancer | >80% LDH release at 15 μM |
| dbacp08143 | MccJ25-18-4 | GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL | Synthetic | Apoptosis inducing | MTT assay | MCF-7 | Breast Cancer | IC50 = 14.2 ± 1.5 μM |
| dbacp08144 | MccJ25-18-4 | GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL | Synthetic | Apoptosis inducing | MTT assay | MDA-MB-435 | Breast Cancer | IC50 = 20.0 ± 0.5 μM |
| dbacp08145 | MccJ25-18-4 | GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL | Synthetic | Apoptosis inducing | MTT assay | MDA-MB-435-MDR | Breast Cancer | IC50 = 25.0 ± 0.5 μM |
| dbacp08147 | Bothropoidin | Not Available | Bothrops pauloensis snake venom | Bothropoidin inhibits breast cancer progression | MTT assay | MDA-MB-231 | Breast Cancer | 30% cytotoxicity at 100 μg/mL |
| dbacp08148 | Bothropoidin | Not Available | Bothrops pauloensis snake venom | Bothropoidin inhibits breast cancer progression | Apoptosis assay | MDA-MB-231 | Breast Cancer | Early apoptosis at 10 μg/mL and Late apoptosis at 40 μg/mL |
| dbacp08149 | Bothropoidin | Not Available | Bothrops pauloensis snake venom | Bothropoidin inhibits breast cancer progression | Cell migration assay | MDA-MB-231 | Breast Cancer | Inhibited cell migration by 45% at 10 μg/mL |
| dbacp08150 | CIGB-552 | HARIKpTFRRlKWKYKGKFW | Synthetic | Not Available | Sulforhodamine B assay | MCF-7 | Breast Cancer | IC50 = 379.1 ± 8.6 µM |
| dbacp08170 | Peptide - 1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | MCF-7 | Breast Cancer | IC50 = 6.2 µM |
| dbacp08182 | Peptide - 2 | GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR | Synthetic | Not Available | CellTiter-Glo assay | MCF-7 | Breast Cancer | IC50 = 7.0 µM |
| dbacp08190 | Peptide - 3 | GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn | Synthetic | Not Available | CellTiter-Glo assay | MCF-7 | Breast Cancer | IC50 = 4.6 µM |
| dbacp08198 | Peptide - 4 | GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab | Synthetic | Not Available | CellTiter-Glo assay | MCF-7 | Breast Cancer | IC50 = 3.0 µM |
| dbacp08206 | Peptide - 6 | GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | MCF-7 | Breast Cancer | IC50 > 7.5 µM |
| dbacp08214 | Peptide - 7 | GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR | Synthetic | Not Available | CellTiter-Glo assay | MCF-7 | Breast Cancer | IC50 > 7.5 µM |
| dbacp08222 | Peptide - 8 | GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK | Synthetic | Not Available | CellTiter-Glo assay | MCF-7 | Breast Cancer | IC50 > 7.5 µM |
| dbacp08230 | Peptide - 9 | GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK | Synthetic | Not Available | CellTiter-Glo assay | MCF-7 | Breast Cancer | IC50 > 7.5 µM |
| dbacp08238 | Peptide - 10 | GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | MCF-7 | Breast Cancer | IC50 > 7.5 µM |
| dbacp08246 | Peptide - 11 | KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) | Synthetic | Not Available | CellTiter-Glo assay | MCF-7 | Breast Cancer | IC50 = 7.3 µM |
| dbacp08254 | Tr1 | Not Available | Protein extraction from Spirulina platensis | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 = 60.12 μg/mL |
| dbacp08256 | Tr2 | Not Available | Protein extraction from Spirulina platensis | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 < 31.25 μg/mL |
| dbacp08260 | Tr4 | Not Available | Protein extraction from Spirulina platensis | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 = 238.86 μg/mL |
| dbacp08296 | BnSP-6 | SLFELGKMILQETGKNPAKSYGAYGCNCGVLGRGGPKDATDRCCYVHKCCYKKLTGCDPKKDRYSYSWKDKTIVCGENNPCLKELCECDKAVAICLRENLGTYNKKYRYHLKPFCKKADPC | B. pauloensis | Not Available | MTT assay | MDA-MB-231 | Breast Cancer | 45% cell cytotoxicity at 100 μg/mL |
| dbacp08299 | SKACP003 | FPLPCAYKGTYC | Synthetic | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 = 193 ± 0.5 µM |
| dbacp08300 | SKACP003 | FPLPCAYKGTYC | Synthetic | Not Available | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 212 ± 0.5 µM |
| dbacp08301 | SKACP003 | FPLPCAYKGTYC | Synthetic | Not Available | MTT assay | MDA-MB-453 | Breast Cancer | IC50 = 156 ± 0.5 µM |
| dbacp08331 | Sample Peptide 1 from EP3604345B1 | MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 / WST-8 | MDA-MB-231 | Breast Cancer | Cell Viability = 62.3% at 25 μM |
| dbacp08339 | Sample Peptide 3 from EP3604345B1 | MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 / WST-8 | MDA-MB-231 | Breast Cancer | Cell Viability = 81.7% at 25 μM |
| dbacp08380 | IDP-LS13 | RKRRNDLRSRFLALRDQ | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | MCF-7 | Breast Cancer | EC50 ~ 10 μM |
| dbacp08424 | 5-2C | NYPQRPCRGDKGPDC | Synthetic | Not Available | MTT assay | MCF-7 | Breast Cancer | IC50 = 9.74 μM |
| dbacp08425 | 5-2C | NYPQRPCRGDKGPDC | Synthetic | Not Available | MTT assay | MDA-MB-231 | Breast Cancer | IC50 = 0.8061 μM |
| dbacp08429 | hBD3-3 M1 | GKCSTRGRKCMRRKK | Synthetic | Not Available | Cell Proliferation assay | MDA-MB-231 | Breast Cancer | Concentration dependent reduction in colony formation between 100 μM and 200 μM. |
| dbacp08430 | hBD3-3 M1 | GKCSTRGRKCMRRKK | Synthetic | Not Available | Annexin V/ PI staining assay | MDA-MB-231 | Breast Cancer | Inhibition in growth by apoptosis as cells positive for annexin V formed 50% of test group |
| dbacp08431 | hBD3-3 M2 | GKCSTRGRKMCRRKK | Synthetic | Not Available | Cell Proliferation assay | MDA-MB-231 | Breast Cancer | Concentration dependent reduction in colony formation between 100 μM and 200 μM. |
| dbacp08432 | hBD3-3 M2 | GKCSTRGRKMCRRKK | Synthetic | Not Available | Annexin V/ PI staining assay | MDA-MB-231 | Breast Cancer | Inhibition in growth by apoptosis as cells positive for annexin V formed 50% of test group |
| dbacp08439 | Balixafortide | ACSAp(Dab)RYCYQKpPYH | Synthetic | Not Available | HUVEC sprouting | MDA-MB-231 | Breast Cancer | IC50< 20 nM |